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ABSTRACT 
Kai Chen: A Biomimetic Approach toward Red Blood Cell Substitutes Based on PRINT 
Hydrogels  
(Under the direction of Joseph M. DeSimone) 
This work utilized PRINT (particle replication in non-wetting templates) technology to 
fabricate extremely soft, biologically inspired hydrogel particles that mimicked the size, shape 
and modulus of red blood cells (RBCs). Hemoglobin, the oxygen carrying protein in RBCs, was 
conjugated into these microparticles without adverse effect on the structure and function of the 
protein. A prior modification on surface of PRINT particles followed by hemoglobin conjugation 
enabled the protein-laden microparticles to circulate in blood. The results of this study can 
potentially lead to a RBC substitute for blood transfusion without causing vasoconstriction, a 
major hurdle often seen in other hemoglobin-based oxygen carriers (HBOCs). 
Vasoconstriction is believed to be inversely proportional to the size of the HBOC. 
Microparticles with size around or larger than 1 µm may be appropriate as hemoglobin carriers 
to minimize vasoconstriction, yet they generally do not circulate well in blood vessels due to 
filtration by small capillaries. Our previous study demonstrated that microparticles with a 
diameter of 6 µm could still circulate a long time in blood when they were made to be 
deformable enough. 
Retaining the same low modulus, hydrogel particles with diameters ranging from 0.8 to 
8.9 µm were studied on their pharmacokinetics and biodistribution in mice. The particles 
mimicking size of RBCs demonstrated longer circulation times, hence were used as carriers for 
iv 
hemoglobin in this study. Bovine hemoglobin could be conjugated to the RBC mimicking 
particles (RBCMs) through reaction between carboxyl groups in the particles and amine groups 
on hemoglobin.  
However, hemoglobin distributed on the surface of the RBCMs made them tend to 
aggregate in blood and more recognizable by macrophages, resulting in rapid removal from 
circulation.  A strategy was used to synthesize blank RBCMs with such an asymmetric 
distribution of carboxyl groups that most of them were in the interior with limited exposure on 
the exterior. After conjugation, hemoglobin could be predominantly confined in the interior of 
the particles with a neutral surface charge. These particles could circulate in blood with much 
lower accumulation in the lung than the counterparts with hemoglobin on their surface.  
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE OF RBC SUBSTITUTES 
1.1 Physiology of Blood and Red Blood Cell 
A human can live up to 3 weeks without food, 3 days without water, yet only 3 minutes 
without oxygen. Blood, responsible for delivering oxygen to tissues and cells, is undoubtedly a 
vital body fluid. Blood also delivers nutrients to the cells of the body, as well as transports 
carbon dioxide and other waste products away. It also helps fight infection in the body.1 Blood 
undergoes gas exchange in the lung, and is pumped by the heart through a network of arteries 
and veins. Even the heart cannot survive without blood flowing through the vessels that bring 
oxygen and nourishment to its muscular walls.  
Blood accounts for 7% of the human body weight with roughly 5 liters in volume in 
average adult. It is composed of blood cells (red blood cells, white cells, platelets) suspended in 
plasma. Plasma, a yellowish fluid constituting 55% of blood volume, contains 90% water, 8% 
proteins, and trace amounts of other materials including salts, nutrients, hormones and waste 
products. The erythrocytes, or red blood cells (RBCs), make up the largest population of blood 
cells, constituting about 45% of whole blood volume. There are about 1000 times more RBCs 
than white blood cells. Regarding numbers per µL of blood, there are 4.7 to 6.1 million RBCs in 
a male, 4.2 to 5.4 million in a female. 
RBCs are the gas transporting component in blood. They are originally produced in the 
bone marrow in a process called erythropoiesis,2 which lasts about 7 days. As adults, 
erythropoiesis is limited to the larger bones while almost every bone produces RBCs during 
childhood. In adults, approximately 2.4 million new RBCs are produced per second. Mature 
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RBCs lack a nucleus and mitochondria and are not able to undergo mitosis or cytokinesis (cell 
division), repair themselves, or generate proteins. They are flexible and have a shape of 
biconcave disk, with diameter of 6-8 µm, height of 1-2 µm and a volume of 90 fL.3 The unique 
shape allows RBCs to stack like plates and bend as they flow smoothly through the narrow blood 
vessels.4 
RBCs circulate for about 120 days in the body and undergo thousands of trips through the 
microvascular vessels that are smaller than the RBC diameter, because RBCs are capable of 
extreme changes in shape, deforming over 100% to navigate the small vasculatures.3  Toward the 
end of their 120-day journey, catabolic changes occur within RBCs and they lose some of their 
flexibility and ability to deform.5 Clearance of senescent RBCs occurs mainly in the spleen, 
phagocytically by macrophages in the red pulp of the spleen6,7. Defective RBCs, for example 
malaria-parasitized RBCs, are also eliminated similarly like senescent RBCs. Changes of RBC 
mechanical properties have also been observed in stored blood over 3 weeks.8 Prolonged storage 
influences the survival of RBCs after transfusion and probably contributes to transfusion-related 
side effects such as respiratory distress and systemic sepsis.  
Deformability of RBCs can be attributed to the architecture of the RBC membrane.9 The 
membrane is chiefly composed of a phospholipid bilayer with a loose lattice of spectrin and actin 
attached on the inside surface likely giving the red blood cells their signature shape and 
mechanical properties.  The membrane also possesses several proteins which are considered to 
be “markers-of-self”; they down-regulate endocytotic pathways and prevent these cells from 
being cleared by the Mononuclear Phagocyte System (MPS), promoting long circulation times10.   
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1.2 Structure and properties of Hemoglobin 
Vertebrate RBCs contain Hemoglobin (Hb), an iron-containing protein, which transports 
oxygen by reversibly binding to oxygen and greatly increasing its concentration in blood.11 In 
contrast, carbon dioxide, the metabolic waste gas, is dominantly (>90%) transported 
extracellularly by dissolving in plasma as bicarbonate ion.12 As the major component of the 
RBC, there are about 200 million Hb molecules in a single RBC, making up 35% of the total 
content (water included), and about 97% of the RBC’s dry content. As such, RBCs are little 
more than containers of Hb. The Hb concentration in human blood is around 12-16 g/dL.13  
The protein Hb is made up of 4 globin subunits, each of which compose of a protein 
chain tightly associated with a non-protein heme group (Figure 1.1A).11 As a tetramer, Hb 
consists of two α and two β subunits, each made of 141 and 146 amino acid residues 
respectively, denoted as α2β2.  The subunits are structurally similar with a molecular weight of 
about 16,000 Da, and are connected through Van der Waals forces, hydrogen bond and salt 
bridges. A heme groups consists of an iron ion centrally held in a porphyrin ring. The iron ion is 
the exact site of oxygen binding and its binding states dictate the color of blood. Hb also carries 
carbon dioxide (5-10%), which however, binds to the globin chains rather than iron ion. The iron 
ion may be either in the Fe2+ (ferrous) or in the Fe3+ (ferric) state, but ferricHb cannot bind 
oxygen. FerricHb is specifically termed as metHb (metHb).14 Within RBCs, there is a 
complicated machinery involving enzymes like metHb reductase, superoxide dismutase and 
catalase that work together to ensure no more than 3% metHb is present at any given time.  
There is an exquisitely well-adapted mechanism for oxygen coordination and transport by 
Hb. Dioxygen coordination by Hb is accompanied by minute adjustments of the protein from the 
tensed (T-form) deoxyHb conformation to the relaxed (R-form) oxyHb conformation in which 
access to the heme pocket is more open, increasing the affinity to O2. Release of O2 is 
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accompanied by changes of Hb’s conformation back from the R to the T form, reducing its 
affinity for O2, facilitating oxygen off-loading. The partial pressure of oxygen (pO2) affects O2 
affinity, where at high pO2 (such as those present in the alveoli), the R-form is favored. 
Inversely, low pO2 (such as those present in respiring tissues) favors the T-form. As a 
consequence of this cooperativity, the oxygen binding curve of Hb is sigmoidal, or S-shaped 
(Figure 1.1B), as opposed to the normal hyperbolic curve associated with non-cooperative 
binding  
Hb is also allosteric, meaning it can be regulated by an effector molecule at certain 
binding site. It has many negative allosteric effectors, especially 2,3-diphosphoglycerate (2,3-
DPG) that can stabilize the T-form, causing it to release the carried O2. Various factors such as 
low pH, high CO2 and high 2,3-BPG level of the tissues favor the T-form, which has low oxygen 
affinity and releases oxygen in the tissues. Conversely, a high pH, low CO2, or low 2,3-DPG 
favors the R-form which can better bind oxygen. 
Hb’s affinity for oxygen, hence its tendency to release or retain the gas, is usually 
described by the oxygen partial pressure at which 50% of the Hb is saturated (P50).  P50 is 
temperature dependent. The capacity of Hb to release oxygen to tissues decreases rapidly when 
temperature decreases, leading to lower P50. At 37 °C, P50 for purified cell-free human Hb (in 
the absence of 2,3-DPG) is about 14 Torr, as compared to about 26-28 Torr for Hb in the RBC. 
1.3 Blood transfusion 
A blood transfusion, nowadays, is generally considered as a safe, common procedure in 
which people receive blood through an intravenous (IV) line inserted into one of the blood 
vessels. The purpose of blood transfusion is to replace blood lost during a serious injury or 
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surgery, and may also be done if the body cannot make blood properly because of an illness. 
Either whole blood, or blood components, especially RBCs is transfused. 
There has been a long and complex history of blood transfusion. It is only after 
Landsteiner’s discovery of the ABO blood group system in 1900 that blood transfusion started to 
become safe. Blood banking became possible when anti-coagulants were added to collected 
blood, and now about 107 million blood donations are collected worldwide. The shelf-life of 
collected blood in fridge is generally regarded as 42 days. 
Each year, nearly 85 million units of RBCs are transfused worldwide every year.  In the 
US alone, blood is needed every two seconds and the need for blood donations increases every 
year.15,16  Although an overall annual surplus of RBCs is reported in the U.S., this does not take 
into account geographic or chronologic variations or the availability of RBCs for patients with 
special RBC requirements. In fact, 13.2% of hospitals have reported challenges in RBC supply.17 
As such, it appears to be challenging for donor centers to consistently maintain RBC inventories, 
and these facilities may have difficulty maintaining the optimum three-day supply.   
RBC transfusions are under increasing scrutiny regarding efficacy associated with the 
storage lesion, which refers to the biochemical, biomechanical, and immunologic changes in 
stored RBCs.18,19  Stored RBCs are accompanied by changes of affinity of Hb for oxygen, 
decrease in pH, hemolysis, changes in RBC deformability, formation of mircoaggregates, release 
of vasoactive substances and denaturation of proteins. The concentration of 2,3-DPG in stored 
RBCs decrease over time and little is left after 2 weeks, making transfusion of stored blood not 
immediately effective in delivery oxygen. It takes about 24 h for banked RBCs to restore their 
2,3-DPG level to about one-half of normal. 
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RBC transfusions are not without risk: fatal adverse transfusion events can occur, such as 
transfusion related acute lung injury (TRALI), hemolytic transfusion reactions, or septic 
transfusion reactions.20 Additionally, there is the risk  of receiving RBCs infected with HIV, 
hepatitis A virus, B19 parvovirus, hepatitis C virus, and infectious prion proteins among other 
known and emerging pathogens.21  Beyond the spread of diseases, if a person has a medical 
condition that requires repeated RBC transfusions, such as patients with sickle cell disease, they 
may develop alloantibodies to donor RBC antigens: alloimmunization occurs in about 1 out of 4 
people who are afflicted with sickle cell disease.22  Lastly, the safety of the RBC donor cannot be 
overlooked.  Despite the advances in RBC collections, storage, and transfusions, the severe 
reaction rate associated with donation was 0.09%, and 55 cases of post-donation fatalities have 
been reported to the U.S. Food and Drug Administration (FDA).23  The need to develop safe, 
effective, shelf-stable, and non-immunogenic synthetic blood substitutes is great.  
1.4 RBC substitutes 
The history of blood substitutes date back to the 1600s when beer, wine and milk were 
examined as intravenously administered substitutes for blood.24 It is only after WWII, when 
concern over shortage of blood grew, that research on blood substitutes started to begin, and was 
boosted by the outbreak of AIDS in the 1980’s. 
The term “blood substitutes” is a misnomer since the products developed only transport 
gas and replace lost blood volume, while whole blood clearly carries out more functions. As 
such, RBC substitutes or oxygen therapeutics would be more proper to describe these products. 
There are two major types of RBC substitutes: perfluorocarbon (PFC)-based oxygen carriers and 
Hb-based oxygen carriers (HBOC). 
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Perfluorocarbons (PFC) are chemically and biologically inert molecules containing 
primarily, fluorine and carbon atoms.25,26  They are capable of dissolving large amounts of many 
gases, including oxygen. Since PFCs cannot dissolve in water, they are formulated into 
emulsions containing surfactants, salts and other additives.27 PFCs demonstrate a linear oxygen 
dissociation curve in contrast to the sigmoid dissociation curve of blood. Hence, elevated arterial 
partial pressures of oxygen enhance oxygen transport by these molecules. However, this linear 
relationship can also work as a disadvantage since most of the oxygen is released prior to 
distribution in the capillary network where the partial pressure of oxygen is lower, and hence the 
need for oxygen is greater.  The first PFC product to be approved by the FDA contained 
perfluorodecalin and perfluorotripropylamine emulsified with Pluronic F-68 and called Fluosol-
DA. But due to marginal efficacy, a short effective half-life, temperature instability, low oxygen-
carrying capacity, and adverse effects such as acute complement activation and disruption of 
pulmonary surfactant, this product has since been withdrawn from the market.  A more stable 
emulsion containing perfluorooctyl bromide and perfluorodecyl bromide emulsified in egg yolk 
phospholipid (Alliance Pharmaceutical Corporation (California)) was developed.  This product 
called Oxygent is thermally stable and had oxygen carrying capability 4-5 times greater than 
Fluosol-DA and showed great promise initially. However, phase III trials showed an increased 
incidence of stroke in treated patients compared to controls and trials have been halted.26 
Stroma-free Hb has been investigated as an HOBC since the 1940s, when researchers 
realized that native Hb is not antigenic and has many advantages over red blood cells, including 
the ability to withstand sterilization and a shelf life of approximately 2 years at room temperature 
for some products.  Unfortunately, the initial attempts at transfusing stroma-free Hb produced 
renal dysfunction, coagulopathy, and hypertension. Stroma-Hb is cleared quickly (half-life of 
 8 
0.5~1.5 h) from the circulation by the kidney due to disassociation into two dimers (αβ), causing 
severe renal toxicity.19 Besides, solutions of acellular Hb are not as effective at oxygenation as 
packed RBCs because of their high affinity for oxygen. Adverse effects were attenuated by 
various modifications to the Hb molecule to prevent glomerular filtration and to stabilize the 
molecule to withstand heat and chemical purification during production but even then the 
hypertension was out of proportion to the volume infused. It is thought to result from Hb binding 
to nitric oxide, which is a potent vascular endothelial relaxant.  Several approaches have been 
tried to decrease the avidity with which Hb binds to oxygen. These adaptations include the 
addition of organic phosphate to serve the function of 2,3-BPG and adenosine triphosphate, 
cross-linking dimers of Hb tetramers and polymerizing the tetramers to decrease oncotic pressure 
or recombinant Hb where the two alpha subunits are covalently attached, and prevent glomerular 
filtration (Figure 1.2), but hypertension has remained a significant adverse effect of stroma-free 
Hb.  
PolyHeme (Northfield Laboratories Inc., Evanston, Ill) is a first-generation pyridoxylated 
polymerized Hb made from outdated human blood28.  It has a half-life of 24 hours, a shelf life 
longer than 12 months when refrigerated, and a P50 of 28-30 Torr.  A 720-patient phase III trial 
was conducted in trauma patients in which subjects were randomized to receive either PolyHeme 
or standard of care at the time of injury. Preliminary results indicated that 46 of 349 patients 
treated with PolyHeme died, whereas 35 of 363 patients in the control group died.  FDA denied 
approval of PolyHeme based on the clinical trial results and Northfield Laboratories suspended 
operations. Other first-generation polymerized Hb products include HbOC-201 (Hemopure 
manufactured by Biopure Corporation, Cambridge, Mass) and HemoLink (Hemosol Corporation, 
Mississauga, Canada).  Hemopure is a polymerized form of bovine Hb with a P50 of 30 Torr that 
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is closer to human Hb than stroma-free Hb. It has an intravascular half-life of 8-23 hours and a 
shelf life of 36 months at room temperature. Hemopure is approved in South Africa for the 
treatment of adult surgical patients who are acutely anemic with the intention of eliminating or 
reducing the need for allogenic red blood cell transfusions. In the United States, phase II trials 
have been put on hold due to safety issues. Biopure filed chapter 11 and was purchased by OPK 
Biotech. 
Hemospan (Sangart Inc., San Diego, Calif), also known as MP4OX, is a PEG-conjugated 
human Hb currently undergoing clinical trials in the US and Europe29. MP4OX is designed to 
deliver oxygen in the capillaries, where red blood cells may not naturally reach when the body is 
suffering from trauma-related ischemia, but is not considered to be a substitute for red blood 
cells.  Adverse effects associated with the vasoactive properties of first-generation blood 
substitutes are not seen with Hemospan (MP4OX).  
As an alternative of modified human or bovine Hb, recombinant Hb has been produced 
from microorganisms such as E. Coli, hence is free from mammalian infectious agents. 
Recombinant human Hb was engineered either to have a low oxygen affinity or have the α-
globins fused to avoid disassociation30. These recombinant Hb products advanced to clinical 
trials, but it was stopped due to vasoconstriction and other harmful effects. 
For Hb-based oxygen carriers cross-linked with enzymes, there has been an effort to 
synthesize compounds that not only perform the function of carrying oxygen, as do the 
molecules mentioned previously, but also harbor some of the enzyme activity that normal red 
blood cells possess. Polymerized Hb has been cross-linked with catalase (CAT) and superoxide 
dismutase (SOD) to form a compound that, in animal models can not only carry oxygen but also 
remove oxygen radicals that are responsible for ischemia reperfusion injuries31. PolyHb has also 
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been cross-linked with tyrosinase to form a soluble complex that can carry oxygen and decrease 
the systemic levels of tyrosine32. This agent can help increase the efficacy of chemotherapy and 
radiation therapy in tumor tissue and in a melanoma model has been shown to delay tumor 
growth without having significant adverse effects. 
Efforts have also been made to encapsulate Hb within a lipid-membrane to create a 
compound capable of carrying oxygen while not being associated with significant 
vasoconstriction. These liposomes appear to be retained in plasma for a significant period33. 
However, they are difficult to produce and can activate the reticuloendothelial system, the 
complement pathway, and platelets.  
The most recent development in blood substitutes is the RBC production from stem 
cells34. A French research group demonstrated that the cultured RBCs (cRBCs) could complete 
their maturation when incubated in the necessary in vivo conditions, and the cRBCs had a half-
life of 26 days after injection into human blood. The lifespan and survival rate of the cRBCs are 
similar to conventional RBCs, supporting their validity as a possible source of transfusion35. 
However, scale-up of the production of cRBCs and the overall consumed time and cost remain a 
formidable hurdle (thousands of dollars per unit).36 Therefore, easy-to-scale-up synthesis of 
HBOCs is still intensely appealing.  
The ultimate RBC substitute would contain not only Hb but also other contents of the 
RBC encapsulated in an artificial membrane. However, production of such a product would be 
extremely challenging. Efforts have been made to use synthetic polymer t to create artificial 
RBCs37. These artificial cells contain Hb along with the RBC enzyme complement including 
superoxide dismutase, metHb reductase, and catalase. 
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1.5 PRINT RBC Mimics 
Against the history of RBC substitutes, we proposed a fundamentally new approach to 
the problem of a therapeutically viable RBC substitute. We intended to build truly synthetic 
RBCs consisting of micron-sized particles with the shape, physical properties resembling true 
RBCs. This approach has been enabled by recent breakthroughs in the nanotech world that allow 
us to mold, with nanoscale precision, RBC mimics that are shape-specific, colloidally stable 
particles with dimensions and mechanical properties which resemble true RBCs. 
We have fabricated RBC-mimicking particles without Hb using the PRINT 
technology.38–40  PRINT (particle replication in non-wetting template; Figure 1.3A) is a 
precision-molding technique that can efficiently generate monodispersed particles of desired 
size, shape, chemistry and surface properties. In PRINT, a photocurable liquid 
perfluoropolyether (PFPE), is used as a molding material.  Master templates are prepared using 
traditional photolithography techniques with raised features on size scales from ~55 nm to >100 
µm.  PFPE has an exceptionally low interfacial tension and is able to completely wet such 
templates, at which time it is photochemically cured to produce a crosslinked elastomeric mold 
possessing cavities which mirror the raised features of the master template.  The low surface 
energy of the PFPE molds allows the cavities to be filled with a pre-particle solution without 
wetting the landing area between the individual cavities.  In this way, distinct particles can be 
generated in the absence of a flash (connecting) layer.  Particles can then be removed from the 
mold (harvested) with an adhesive layer such as poly(vinyl alcohol) or polyvinylpyrilidone. 
Dissolving of the soluble polymeric excipient layer can lead to dispersed solutions of particles. 
Using PRINT, hydrogel particles with similar size, shape, characteristics as RBCs of 
mouse were fabricated (Figure 1.3B-E) with tunable deformability. Bulk hydrogels 
corresponding to these particles were made with varying crosslinker, and the modulus of them 
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tested. It was found that these hydrogels particles had dramatically altered behavior in vivo in a 
mouse model due to their different deformability.  The pharmacokinetics (PK) parameters of 
these particles are summarized in Table 1.1. Particles made from this hydrogel material with a 
Young’s modulus of 7.8 kPa were eliminated from the circulation over 30 times slower than 
particles which were only moderately (approximately 8x) stiffer (63.9 kPa). The marked 
difference in the PK of these particles was presumably due to avoidance of filtration in the 
capillary beds of the lungs, and to some extent, the spleen for softer particles, as indicated by the 
fact they were able to deform more than stiffer ones to pass through microfluidic channels that 
were only as half-wide as the particle diameter13.  Because even slightly less elastic particles 
(modulus of 16.9 kPa) had greatly reduced circulation times, a modulus-based threshold for 6 
µm diameter particles to avoid filtration in vivo was inferred.13 
Table 1.1  PK parameters of RBC mimics found through non-linear regression analysis and fit to 
a two compartment model for elimination 
% 
Crosslinker 
Modulus of Bulk 
Material (kPa) 
Distribution 
Half-life (hours) 
Elimination 
Half-life (hours) 
10% 63.9 ± 15.7 0.038 ± 0.0012 2.88 ± 0.92 
5% 39.6 ± 10.4 0.066 ± 0.036 5.12 ± 2.17 
2% 16.9 ± 1.7 0.15± 0.025 7.12 ± 0.82 
1% 7.8 ± 1.0 0.35± 0.13 93.29± 31.09 
 
1.6 Conclusions 
After more than half-a-century’s research for safe, effective RBC substitutes, there is still 
no FDA approved product to date. Most early generations of RBC substitutes relied heavily on 
the modification of the protein, yet the intrinsic problem of vasoactivity could not be 
surmounted. Development in nanotechnology allows nanoparticles to be employed for sustained 
 13 
circulation of hemoglobin in a way that mimics the cellular structure of RBCs, without the need 
to modify Hb structure to avoid problems of free Hb.  By tuning size and surface chemistry of 
nanoparticles, circulation time of these oxygen carriers could be extended to increase the 
efficacy. However, besides liposomes, other nanoparticle based oxygen carriers were not fully 
explored in vivo to fully understand parameters that affect the circulation and biodistribution. 
PRINT, by virtue of its ability to control size, shape, chemistry, surface properties and 
modulus at the same time, enables us to synthesize hydrogel particles, and systematically 
investigate the effect of one factor on the circulation and biodistribution while retaining other 
factors constant.  Maintaining the size of PRINT hydrogel particles similar to murine RBCs, we 
discovered that modulus plays an important role governing the circulation and biodistribution of 
the particles, as softer ones tend to circulate longer than the rigid counterparts as being able to 
navigate smaller capillaries . This in vivo result challenged the long-standing dogma that micron-
sized particles would be quickly removed from circulation, and opens new opportunities for 
using large particles (>1 µm) as possible intravascular delivery system, especially as Hb-based 
oxygen carriers because larger carriers (>500 nm) may be able to minimize vasoconstriction 
inherent to smaller carriers. 
To begin using the RBC mimics as oxygen carriers by incorporating Hb, it will be 
interesting and important to study the circulation and biodistribution of hydrogel particles with 
varying sizes (>500 nm), while retaining similar modulus by using identical compositions. This 
will provide a complete map that can better guide design for not only oxygen carriers, but also 
for drug delivery systems. Based on this PK study, we can further extend the mimicry of RBCs 
by loading Hb into the soft particles with an optimal size, with the potential to control oxygen 
delivery by improving plasma resident time of confined hemoglobin. 
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1.7 Figures. 
        
Figure 1.1  (A) Tetrameric structure of hemoglobin; (B) Hypothetical oxygen-hemoglobin 
dissociation curve. Changes in temperature, pH, and organic phosphates like 2,3-DPG directly 
affect the dissociation of oxygen.   
 
 
 
 
 
 
 
 
 
A B 
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Figure 1.2  Various strategies for modification of the native Hb tetramer (center) intended to 
avoid renal toxicity, increase circulation time of the free tetramer and, often, to modify the 
strength of oxygen binding.  Counterclockwise from top:  1. The two α or β subunits can be 
chemically connected to prevent degradation to the toxic αβ dimer.  2.  Otherwise unmodified Hb 
can be crosslinked to form polyhemoglobin.  3.  Genetic modification allows for fusing of 
subunits as well as tuning of the oxygen binding properties of recombinant Hb.  4.  Polymers 
such as poly(ethylene glycol) or poly saccharides can be chemically attached to the surface of the 
Hb molecule.  5.  Encapsulation in a liposomal carrier or polymeric matrix protects the 
hemoglobin from degradation.  
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Figure 1.3  Blank RBC mimics.  (A) A graphical depiction of the PRINT process to fabricate 
RBC mimics.  Briefly, from top to bottom, an elastomeric fluoropolymer mold (green) with disc 
shaped wells was covered by an aliquot of the pre-polymer mixture (red).  The mold was passed 
through a pressured nip (black) covered by a high energy sheet (grey), wicking away excess 
liquid from the mold surface while filling the wells of the mold.  The filled mold was cured 
photochemically, yielding cross-linked hydrogel particles, which were harvested from the mold 
by freezing onto a thin film of 1% poly (vinyl alcohol) in water (blue) and peeling away the 
mold.  Melting of this layer resulted in a suspension of red blood cell mimic (RBCM) hydrogel 
particles.  (B-E)  Fluorescent images of hydrated RBCMs with varying % crosslinker (B) 10% 
crosslinked (C) 5% crosslinked (D) 2% crosslinked and (E) 1% crosslinked.  Scale bars are 
20µm. 
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CHAPTER 2: PHARMACOKINETICS AND BIODISTRIBUTION OF LOW MODULUS 
HYDROGEL PARTICLES 
 
2.1 Introduction 
It has become a growing area of interest to study the effect of physical properties of nano- 
and microparticles on their in vivo behavior in the circulation, because of the increased attention 
to the design of functional particles for applications in the fields of medical imaging and drug 
delivery.1–3 Many factors, including size, shape, charge, surface chemistry and modulus of 
particles, all influence their circulation behavior.4 Of these mentioned factors, size, is perhaps the 
most studied, though not necessarily the most dominant, factor.  Many important in vivo 
functions of particles as drug carriers depend on particle size: circulation times, extravasation, 
targeting, immunogenicity, internalization, intracellular trafficking, degradation, flow properties, 
clearance and uptake mechanisms.5 
To understand the effect of size of particles on circulation and uptake, it is critical to first 
recognize the biological barriers that may affect particle performance. Biological barriers exist to 
guard the human body from invasion by foreign particles from a systematic level, to the organ 
level, and the cellular level6. At the cellular level of biological barriers, different endocytotic 
modes determine the path of intracellular trafficking through various possible subcellular 
compartments.7 Ligands conjugated to the surface of engineered particles of particular sizes can 
influence the mode of cellular internalization.8 Cellular barriers are the last barrier nanoparticles 
have to overcome, i.e systematic and organ level barriers have already been bypassed. While 
 21 
overcoming cellular barrier is important for most drug delivery systems, it is unnecessary for 
RBC mimics because the particles are desired to stay longer in blood. 
Systematic and organ level barriers are what particles encounter in blood circulation. The 
blood-tissue interface is circumscribed by a layer of endothelial cells, which serve to demarcate 
the vascular and extravascular compartments, and to regulate the flow of solute molecules 
between these compartments9. A continuous endothelium is found in most tissues such as the 
capillaries of all muscles, the central nervous system and the lung, which presents a barrier for 
particles to pass. Exiting of particles from the circulation is normally restricted to fenestrated 
endothelium found in liver and spleen,10,11 or perturbed endothelium caused by inflammatory 
processes or by a tumor; the latter is how enhanced permeability and retention effect comes into 
play in cancer nanomedicine.12 
In the sinusoids of the liver, the vascular endothelium is marked by openings or 
fenestrations at the size of about 100-150 nm13, which allow the ready passage of plasma 
proteins and lipoproteins, even permitting particles of less than about 100 nm to come into 
contact with the hepatocytes. Larger particles remain within the sinusoids where they come into 
contact with Kupffer cells, which are avidly phagocytic and the Kupffer cell population is 
extremely high comprising about 10% of total liver cells14. The abundant blood flow, tortuous 
circulation in sinusoids, and the abundance of Kupffer cells all together make liver the most 
efficient organ in the removal of circulating particles.  
The spleen has two major functions: production of antibodies and clearance of senescent 
RBCs15. The two functions are approximately compartmentalized in the white pulp and the red 
pulp respectively. The red pulp is abundantly supplied with highly phagocytic macrophages for 
clearing old red blood cells. Blood flow slowly percolates into the splenic sinusoids, which are 
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comprised of a tight reticular mesh with interendothelial cell slits that are 200-500 nm in width. 
The large cross-sectional area for flow and slow blood velocity as well as the plentiful 
macrophages all facilitate the trapping of particles. The physical filtration of particles along with 
macrophage uptake in spleen makes it preferentially clear particles larger than 200 nm.  
Macrophages that reside in the liver and spleen are in a good position to capture particles 
passing by, and there are also macrophages circulating that are capable of grasping particles too. 
Opsonization,  that  is  the  adsorption  of plasma protein  ligands  capable  of  interacting with  
one  or more  receptors  on  the  macrophage  cell  surface, is generally believed to be the major 
reason for macrophage recognition of foreign particles16. The opsonin proteins are present 
throughout the blood and are thought to come in contact as soon as particles are administered 
into blood; the binding to a particle surface can happen on a temporal scale ranging from a 
matter of seconds to many days for completion17. The exact mechanism has not been fully 
elucidated; yet, it is know that binding is followed by attachment of phagocyte to particle 
surface. 
 Based on the biological barriers discussed above, an optimal size is necessary for 
particles to avoid filtration by biological systems. The  size  cut-off  for filtration no  doubt varies 
considerably depending  on  animal  species  and  the  deformability of  the  particles  
administered. For particles lacking deformability, the upper limit would be in the range of a few 
microns in diameter (5-15 µm)18.   Particles  above  this  size  are easily cleared  by simple  
physical entrapment  or  filtration,  usually  in  the  lung capillary bed, which has a total surface 
area estimated at 40 m2. Small drugs, hydrophilic polymers, and very small nanoparticles will be 
renal filtered after injection due to their small size, which falls below the cut-off size of the 
kidney (~5.5 nm) as demonstrated using quantum dots studies19. Particles larger than 200 nm 
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would be filtered by the liver and spleen as mentioned above. Generally particle size has to be 
below 200 nm and above 5.5nm to be long circulating, and this has been the ‘gold-standard’ for 
particle design in most drug delivery systems. 
The above results were gained from studies using rigid materials, ranging from metals, to 
resin or thermoplastics such as polystyrene or poly(lactic-co-glycolic acid) (PLGA) particles. 
While self-assembled particles, for example liposomes or micelles, may be made to be soft,20 the 
difficulty in systematically controlling the size impedes a thorough study of similarly soft 
particles with varying sizes. Using the PRINT technology, however, it becomes readily feasible 
to maintain an identical low modulus for different-sized particles that are replicated from molds 
with varying sizes.  
In this study, the behavior of monodisperse populations of extremely soft hydrogel 
particles was probed as particle size was varied in the micron range while composition and 
modulus were maintained as constants.   
2.2 Results and Discussion 
2.2.1 Hydroxyl PEG acrylate Monomers 
Previous work in our group already demonstrated the importance of low modulus of 
particles on circulation time. However the monomer 2-hydroxyethyl acrylate (HEA), used for 
making RBC mimics from a mold with 2 µm disk cavities21, is volatile and cannot be used in 
PRINT process to replicate particles from smaller cavities due to increased surface-to-volume 
ratio22. Attempts to replicate particles from 1µm cavities failed as the mold was mostly unfilled 
due to evaporation of HEA. The attempt to fabricate differently sized soft hydrogel particles 
including nanosized ones necessitated exploration of another photocurable monomer with a 
higher boiling point.  
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The intuitive way to fabricate smaller hydrogel particles is to synthesize analogues of 
HEA with a longer PEG side chain. However we know that longer side chains create a higher 
rotation barrier along the backbone, which may impair the softness of the resulting gel. Thus, we 
limited the side chain to be oligomeric chain (n = 2, 3, or 4; Figure 2.1) of PEG groups. 
Rigorous purification of the HPA monomers was necessary to remove all of the diacrylate 
crosslinker, and cold storage ensured that the transesterified diacrylate did not form in situ.   The 
properties of crosslinked hydrogels derive not just from the crosslink density of the gels, but also 
from the properties of the main-chain polymer and the amount of water uptake or swelling.   
Table 2.1 Properties of lightly crosslinked hydrogels composed of different acrylic monomers 
containing 1% of a 4,000 g/mol PEG diacrylate crosslinker and 1% of HCPK photoinitiator, 
hydrated for 12 hours in deionized water at room temperature.  Monomers are shown with 
increasing PEG chain length. 
 
The HPA monomers were successfully synthesized and confirmed by NMR and MS. 
Bulk samples based on HPA with 1% PEG4k diacrylate as crosslinker, 1% 1- hydroxycyclohexyl 
phenyl ketone (HCPK) as UV initiator were made and the resulting hydrogels after soaking in 
water after 24h were tested for mechanical properties, which are summarized in Table 2.1.  
Though HP4A hydrogels should have a greater hydrophilic character than HP3A hydrogels, the 
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longer PEG chain resulted in decreased water uptake, possibly because of the rotation barrier and 
entanglement impeding higher swelling. 
2.2.2 Low Modulus HP3A Hydrogels 
Based on previous work with low modulus hydrogels23, an elastic modulus of < 20 kPa 
was targeted for HPA based hydrogels.  With deformability similar to that of RBCs (15-26 
kPa)24,25, a modulus in the target range should be sufficient to show a large effect on particle 
circulation with 6 µm diameter particles.  An acid containing monomer (2-carboxyethyl acrylate, 
CEA) was included in the hydrogel monomer mixture at 10 % (by weight) to give the particles a 
negative charge, thereby decreasing non-specific particle uptake.26  Bulk samples of HPA 
hydrogels containing 10% CEA monomer, 1% HCPK and crosslinked with PEGDA (MW=4k 
and 6k Da) were hydrated in pH 7.4 PBS to simulate physiological conditions and tested with the 
Instron tensometer (Table 2.2).   
No significant difference was observed between the two different crosslinkers. Since 
PEG4kDA dissolves more easily in HP3A than PEG6kDA, it is the preferred crosslinker to make 
particles. From the modulus data, we can see all the samples demonstrated modulus similar to 
RBCs. 
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Table 2.2  Mechanical properties of HP3A hydrogels with varying amounts of PEG4kDA 
crosslinker and 10% of 2-carboxyethyl acrylate.  Swelling ratios were determined from one bulk 
sample hydrated for 24 hours in PBS.  Modulus and strain at break represent an average value 
determined from three samples cut from the bulk gel, with error representing one standard 
deviation. 
 A B C D E F  
HP3A 88 88.5 88.95 88 88.5 88.9  
PEG6kDA - - - 1 0.5 0.1  
PEG4kDA 1 0.5 0.05 - - -  
CEA 10 10 10 10 10 10  
HCPK 1 1 1 1 1 1  
E (kPa) 17± 2.2 13 ± 1.6 6.5± 1.3 17 ± 2.7 16 ± 1.5 12 ± 0.9  
% strain at break 53 ± 19 46 ± 7 43± 7.5 50 ± 8 40 ±7 38 ± 8  
Swelling ratio (wt) 11.9 12.8 30 12.9 12.8 19.2  
Swelling ratio (length) 2.4 2.6 3.5 2.5 2.5 2.8  
2.2.3 RBC-sized HP3A Particles 
According to the swelling ratio of bulk samples, PFPE mold with 2 µm cavities may 
generate RBC mimics with a similar size to those of mouse RBCs (5~6 µm).  In a typical PRINT 
process, polymerizable liquid based on composition of Table 2.2 were used to fill the PFPE 
mold and UV cured. The particles were then transferred onto poly(vinyl alcohol) (PVOH) film 
and then harvested into PBS. Depending on the amount of crosslinker in the composition, 
particles with slightly different sizes were obtained in the range of 5~6 µm in diameter and 
1.6~1.8 µm in thickness. In Figure 2.2(A-C), particles with 0.25 wt% PEG4kDA in different 
stages of the fabrication process: in the mold, transferred onto PVOH and suspended in PBS, 
were imaged with a fluorescent microscope. The soft nature of the particles could be visualized 
by SEM: Figure 2.2D illustrates that the particles with 1 wt% crosslinker collapsed and spread 
on the substrate. When the crosslinker density dropped to 0.5 wt%, however the dried sample 
could not be visualized using SEM because at such a low crosslinking density, the particles were 
unable to withstand the surface tension during drying process which tore them apart into broken 
pieces.  
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To obtain long circulation times, the deformability of the hydrogel particles must provide 
them with the ability to pass through smaller capillaries than their size as well as the 
fenestrations in the spleen in vivo. Before in vivo study, we utilized a microfluidic device with 
constricted passages to study the in vitro flow behavior mimicking what they might experience in 
traversing the microvasculature. Microfluidic devices modeling the vascular constrictions have 
been explored to evaluate the behavior of cells27, including natural and diseased RBCs28, and 
synthetic RBC mimics29. A 3-µm tall channel packed passages that were 3 µm wide and 50 µm 
long and repeated many times was designed. There was also an unrestricted 15-µm wide path on 
each side of the restrictions running the length of the channel, providing an unhindered path for 
fluid flow to maintain reasonably low pressure through the constricted pathways (Figure 2.3A). 
A dispersion of 0.5 wt% PEG4kDA-crosslinked hydrogels (avg. diameter 5.4 µm) in PBS 
(containing 0.1 wt% PVOH) was tested in the channel at a flow rate of 0.1 mL/min controlled by 
a syringe pump. Using an inverted microscope, movies depicting the particles passing through 
the passages were taken. The image sequence in Figure 2.3B shows two particles traversing the 
passages: the particles stretched in the passages with an elongated shape followed by relaxation 
to the original discoid shape after exiting the passages. Particles with other crosslinker densities 
(from 1%-0.05%) were all tested in microfluidic devices and all demonstrated squishy 
characteristics that allow them to pass through channels narrower than their size. 
2.2.4 Low Modulus HP3A Particles with Varying Sizes 
The hydrogel formulation with the lowest modulus, as column C in Table 2.2, was used 
to fabricate super soft hydrogel particles, including 1% Dylight 680 maleimide for in vivo 
imaging, and 0.1% methacryloxyethyl thiocarbonyl rhodamine B for ease of particle analysis. To 
understand the effect of size on biodistribution of similarly soft particles, PRINT molds with 
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discoid wells of varying diameters of 0.2, 1, 2 and 3 µm were used to generate particles with 
hydrated diameters of 0.78, 3.79 ± 0.17, 6.39 ± 0.56, and 8.88 ± 0.47 µm in PBS, respectively 
(Table 2.3).   
Fluorescent microscopy was used to measure the diameter of hydrated particles (n=50) 
for all except those molded at 0.2 µm.  These particles were too small to accurately measure by 
fluorescence microscopy, but were evaluated using dynamic light scattering to determine their 
hydrodynamic diameter.  The zeta potential of the particles was approximately -20 mV in all 
cases.  The particles were suspended in 0.1 wt% 2,000 g/mol poly (vinyl alcohol) in PBS for in 
vivo applications.  Fluorescent images of the low modulus particles can be seen in Figure 2.4. 
Table 2.3  Characterization of particles fabricated for in vivo studies.  Particles molded from 1, 2 
and 3 µm features were measured by microscopy, with error representing one standard deviation 
from the mean with n=50 for particle diameters.  Particles molded at 0.2 µm were measured by 
dynamic light scattering to determine their hydrodynamic diameter. 
Mold diameter Particle Diameter Zeta Potential 
0.2 µm 0.78 µm (PDI=0.219) -17.9± 7.8 mV 
1 µm 3.79 ± 0.17 µm -22.1 ± 5.7 mV 
2 µm 6.39 ± 0.56 µm -17.6 ± 10.8 mV 
3 µm 8.88 ± 0.47 µm -22.9 ± 7.47 mV 
2.2.5 Biodistribution of Soft Hydrogel Particles with Different Sizes 
To examine the distribution and clearance profile of the particles, female Balb/c mice 
were injected intravenously at a dose of 20 mg particles/kg of body weight.   The mice were 
sacrificed at time points of 0.2, 0.5, 1, 3, 7, 25, 56, and 104 hours post-dose and the tissues 
analyzed for fluorescent signal from the particles (Figure 2.5 and Figure 2.6).  The tissues were 
not perfused prior to analysis.  
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The smallest particles (hydrodynamic diameter = 0.78 µm) distributed primarily into the 
spleen and liver after injection.  Particle accumulation in these tissues increased after injection, 
peaking 1 hour after dosing (Figure 2.5).  After this initial 1 hour period, the signal in these 
tissues decreased steadily over the remaining 103 hours of the study.  Clearance to the spleen and 
liver seems to have been the main mechanism of distribution for these particles, as the initial 
concentration in the blood dropped rapidly over the first hour post-dose.  Accumulation in the 
lungs, heart and kidneys was minor over the course of the study.  The particles were mostly 
concentrated in the spleen, though more total particles were sequestered in the liver.  This 
difference can be seen in comparing Figure 2.5 and Figure 2.6, which present the biodistribution 
data on a per tissue and per gram of tissue basis, respectively.  After 104 hours, the particles 
were largely cleared from the blood, with only 3.4% of the dose still circulating.   
Particles with a hydrated diameters of 3.8 µm distributed primarily into the spleen and 
lungs immediately after injection.  While signal in the lungs decreased after injection, signal in 
the spleen increased, peaking at 3 hours and staying fairly constant or slightly decreasing over 
the next 101 hours.   These particles accumulated to some extent in the liver over the course of 
the study, with signal peaking 24 hours after injection and decreasing slightly thereafter. Liver 
accumulation was minor when viewed on a per gram basis (Figure 2.6).  Accumulation in the 
kidneys and heart remained low at all times, decreasing over the course of the scan, possibly due 
to the small amount of blood remaining in these tissues.  Particles were cleared to low, but still 
measurable, levels in the blood by the final time-point examined, with 4.1% of the injected dose 
in the blood at 104 hours.   
Particles with 6.4 µm diameters distributed primarily into the spleen and lungs 
immediately after injection with a profile similar to what we observed in previous studies with 
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low modulus particles of this size.  Signal in the lungs decreased after injection to low levels.  
Signal in the spleen and liver increased after injection, with signal in the spleen peaking at 3 
hours and the signal in the liver peaking later, 7 hours after injection. Signal in the spleen dipped 
at the 24 hour time-point, correlating to an increase in signal in the blood.  This effect may have 
been due to the release of physically entrapped particles from the spleen back into the 
circulation.  Accumulation in the kidneys, heart, and muscle tissue remained low at all times, 
decreasing over the course of the scan, possibly due to the small amount of blood remaining in 
these tissues.  At the final time-point examined, 104 hours post-dose, 13.2% of the injected dose 
remained in the blood.    
The largest particles, with hydrated diameter of 8.8 µm, were sequestered primarily in the 
lungs after injection, likely due to their large size compared to the diameter of the capillary beds 
in this tissue, and only low amounts of particles remained in the circulation. Particles cleared 
from the lungs over the course of the study, with accumulation in the spleen and liver increasing 
over time.   Liver accumulation was the most significant for these larger particles compared to 
the other sizes examined, especially when viewed on a per gram basis (Figure 2.6).  As with the 
6.4 µm diameter particles, a dip in the amount of particles in the spleen and a corresponding 
increase in the blood occurred.  For these larger particles, this effect was more dramatic, and 
happened earlier in the study (7 hours post-dose).  These particles were largely cleared from the 
circulation to below quantifiable levels by 24 hours post injection, correlating to less than 3% of 
the injected dose. It is noteworthy that even after 104 hours, the micron-sized particles seemed to 
be still retaining their shape in the MPS organs (Figure 2.8), indicating robust particle structure 
to withstand shear forces in vivo. 
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2.2.6 Pharmacokinetics of Soft Hydrogel Particles with Different Sizes 
Particle concentration in the blood was determined from blood drawn via cardiac 
puncture at each time-point.  Serial dilutions of particles in freshly drawn mouse blood allowed 
for the generation of standard curves which correlated fluorescent signal in whole blood to 
particle concentration.  The signal from blood harvested from dosed mice fell within the linear 
region of these plots in most cases, with late time-points falling below quantification limits 
(where the plot deviated from linearity due primarily to interference from autofluorescence in 
blood) for the case of the 8.9 µm particles.  A plot of particle concentration in whole blood over 
time for the four sets of particles is shown in Figure 2.7. 
To evaluate the kinetics of clearance for the 0.78, 3.8 and 6.4 µm diameter particles, we 
used a two compartment pharmacokinetic model (Table 2.4), characterized by a bi-exponential 
decrease in particle concentration over time,30 with parameters fit by non-linear regression 
analysis.31  This model, which has often been appropriate to describe the behavior of particles in 
the circulation,23,32 describes an initial (distribution) phase where the particles distribute from the 
plasma into various tissues, followed by a late (elimination) phase that describes the ultimate 
clearance of particles from the plasma.  For small molecules and nanoparticles the distribution is 
attributed to extravasation into tissue; because of their size, the distribution of our hydrogel 
microparticles may be due to physical entrapment in constricted capillaries (as in the lung) or 
tissues with low blood flow (such as the spleen and liver) rather than by an extravasation 
process.   
The clearance profiles were somewhat similar for each of the particles examined, with 
much of the dose distributing to tissues rapidly after injection and slow elimination half-lives.  
Elimination half-lives (βt1/2) for the smaller particles, 31 and 60 hours for the 0.78 and 3.8 µm 
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particles, respectively, were shorter than for the red blood cell-(RBC) sized 6.4 µm particles (85 
h), suggesting that this size may crucial to the long circulation times of RBCs.  Additionally, the 
area under the curve (AUC), was more than 3 times greater for the RBC sized particles than the 
smaller hydrogels (8.5 compared to 2.5 and 1.7 mg*hr/mL, respectively), indicating that a much 
greater amount of particles stayed in the circulation over time.   Parameters calculated with this 
model can be seen in Table 2.4.  
Table 2.4  Pharacokinetic parameters for low modulus hydrogel PRINT particles with increasing 
diameters.  Parameters were determined from particle concentration in whole blood at times 0.2 -
104 hours post-dose using a standard two-compartment model. 
Particle Diameter 
(µm) 
0.78 3.79 6.39 
A (mg/mL) 0.309 0.152 0.109 
B (mg/mL) 0.0353 0.0268 0.0682 
α (hr-1) 2.88 0.76 1.08 
β (hr-1) 0.0224 0.0116 0.00810 
αt1/2 (hr) 0.2 0.9 0.6 
βt1/2 (hr) 31.0 59.6 85.5 
VC (mL) 1.16 2.25 2.26 
AUC (mg*hr/mL) 1.69 2.50 8.51 
CLT (mL/hr) 0.24 0.16 0.047 
Vdβ (mL) 10.60 12.68 5.73 
 
The circulation profile of the largest particles examined in this study (8.8 µm) could not 
be described by a pharmacokinetic model because these were rapidly cleared below the limits of 
quantification, leaving too few data points for such analysis.  These particles did not appear as if 
their clearance profile would be well described by a standard pharmacokinetic model due to the 
increase in particle concentration in blood at 3 and 7 hours, the explanation of which may require 
the application of more complicated  models.33 This effect of increases in particle concentration 
in the blood at later time points, correlated to decreases in particle signal in either the lungs of 
spleen in all cases.  This strongly suggests that these deformable particles are physically trapped 
in these tissues, and are able to dislodge and re-enter the main circulation.   
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2.3 Conclusions and Future Directions 
  The above studies have shown the promise of HPA based hydrogels for PRINT 
applications where extremely low modulus particles are desired.  Hydrogels made from HP3A 
were fabricated over a physiologically relevant range of modulii by varying the amount of 
PEG4kDA crosslinker. Particles with extremely high levels of deformability, characterized by a 
Young’s modulus of 6.5 kPa, are able to avoid or escape filtration when injected intravascularly 
in mice.  Evidence of avoidance is clear from the long (>30 hours) elimination half-lives of all 
but the largest of these particles.   
The decrease in clearance rate is also clearly seen, as these particles tended to accumulate 
into the spleen over time, reaching a maximum value then decreasing.  The decrease in 
accumulation in the spleen correlated with an increase in the concentration of particles in the 
blood, presumably due to the release of some of the physically entrapped particles. This was seen 
most dramatically in the largest of the microgels studied (8.9 µm), where the particle 
concentration decreased for the first hour of the study before increasing at the 3 and 7 hour time 
points, presumably due to the escape of particles from the lungs and spleen, which resulted in a 
corresponding decrease in particle accumulation.  Finally, higher circulation persistence and 
slower clearance were seen for deformable particles that resembled red blood cells in size than 
for both larger and smaller particles, indicating that this combination of size, shape and 
deformability results in particles that are better adapted to the avoidance of natural clearance 
mechanisms in the body.  
The results presented here demonstrate the importance of size and deformability for 
determining the biodistribution and circulation persistence of hydrogel particles.  This 
information is expected to have a large impact on the design of hydrogel particles for therapeutic 
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or diagnostic applications and to provide a foundation for the use of such highly deformable 
particles for drug delivery.   
The differences in PK and biodistribution among the particles of different sizes indicate 
the importance of size effects, which are affected synergistically by the flow dynamics and 
macrophage interactions. From the aspect of flow dynamics, 6.4 µm particles might have 
performed similarly to real RBCs in vasculatures in a sense that they were mostly in the center of 
blood vessels as defined by the Fåhræus–Lindqvist effect34. Hence, they had less opportunity to 
marginate to blood vessel walls in liver sinusoids where Kupffer cells reside, while in spleen 
they had to pass through the pores that were guarded by macrophages. To study the distribution 
of the different particles in the cross-section of blood vessel, we may use intravital microscope to 
observe mouse’s earlobe blood vessel, and see fluorescence pattern from RBC-sized particles 
and another-sized particle differently labeled. The smaller particles (3.79 µm, 0.78 µm) may tend 
to marginate more to the blood vessel wall than the RBC-sized particles. 
The interaction between HP3A particles and macrophages in the spleen and other organs 
is not discussed here. It has been known that macrophages would have difficulty engulfing soft 
particles than rigid ones. Size also plays pivotal role regarding phagocytosis of particles by 
macrophages. Larger particles would be more difficult to engulf because macrophages need to 
deform the membrane more. By doing the same PK and BioD studies in mice with temporarily 
depleted macrophages by injecting clodronate liposomes, altered circulation profile and 
biodistribution of these hydrogel particles may be observed,35 and can indicate the different roles 
played by physical sequestration of particles versus macrophage internalization. 
All the particles were highly porous because of their high swelling. This characteristic 
may allow large cargoes like proteins, to diffuse into the interior. Different strategies can be 
 35 
employed to secure the cargo inside. Proteins and nucleic acids can be secured within hydrogels 
that are oppositely charged due to electrostatic interactions. Pro-drug strategy can also be used to 
covalently link the cargo to the particle matrices. Degradation of the linker, either by low pH or 
reductive environment, could trigger release of the cargo. For hemoglobin, it is desirable to 
secure the protein inside without leaking out. Thus covalent conjugation can be utilized to ensure 
bond formation. 
2.4 Materials and Methods 
2.4.1 Materials 
Acryloyl chloride (97%), triethylene glycol (99%), and 2-carboxyethyl acrylate (CEA, 
97%) were purchased from Sigma-Aldrich and used as received.  Photoinitiators 2,2-
diethoxyacetophenone (DEAP), and 1-hydroxyl-cyclohexyl phenyl ketone (HCPK) were 
purchased from Aldrich and used as received.  Poly(ethylene glycol) diacrylate (PEG4oooDA) 
and methacryloxyethyl thiocarbamoyl rhodamine B (PolyFluor 570) were purchased from 
Polysciences, inc. and used as received.  Dylight 680 maleimide was purchased from Thermo 
Scientific.  All other reagents were purchased from Fisher and were used without further 
purification unless otherwise noted.       
2.4.2 Synthesis of Hydroxy PEG Acrylate Monomers 
Mixtures of hydroxy PEG acrylate and hydroxy PEG diacrylate were obtained by eaction 
of di-, tri-, or tetraethylene glycol and acryloyl chloride in anhydrous dichloromethane under a 
nitrogen purge with triethylamine present as a scavenger for HCl evolved during the reaction.  In 
order to obtain a higher ratio of monoacrylate to the diacrylated product and a good yield, a 7:3 
ratio of  di-, tri-, or tetraethylene glycol to acryloyl chloride was used.36  Addition of acryloyl 
chloride proceeded over 3 hours at room temperature, with stirring allowed to proceed for 
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another 12-15 hours.  The ammonium chloride salts were removed via filtration.  The filtrate was 
washed several times with deionized water to extract the glycols and monoacrylates.  The 
aqueous phase was washed several times with diethylether to extract the monoacrylate.  The 
ether washes were reduced by rotary evaporator in  vacuo, and the product isolated via column 
chromatography.  The product was eluted using a mixture of hexane, ethyl acetate and methanol 
in a 6:3:1 ratio.  Free radical inhibitor 4-Methoxy Phenol  (MEHQ) was added to the product 
fraction at 500 ppm  of total acrylates prior to exhaustive vacuo rotoray evaporation to remove 
all of the residual solvent yielding a clear, colorless to pale yellow liquid.   The acrylic 
monomers are referred to as hydroxyl PEG acrylates, with the length of the PEG chain attached 
to the acrylic moiety denoted by number.  For example, HP4A refers to the tetraethylene glycol 
adduct, while HP2A refers to the diethylene glycol adduct.    
2.4.3 Modulus Testing 
To measure the mechanical properties of crosslinked HPA hydrogels, macroscopic 
coupons of the prepolymer mixtures were polymerized via UV light in a Teflon mold.  
Approximately 650 µL of freshly prepared prepolymer mixture was pipette into a 2.5 x 2.5 cm 
square mold.  The mold was placed in a low-intensity UV oven, and nitrogen purged for 3 
minutes prior to curing with UV light.  The cross-linked hydrogels were removed from the mold, 
weighed, and placed in pH 7.4 PBS buffer for 24 hours to fully hydrate.  The coupons were 
patted dry with paper towels and weighed again prior to sectioning into approximately 10 mm 
wide strips with a razor blade for testing with an Instron 5556 Universal Testing Machine 
(Instron) with a strain rate of 5 mm/min.  Young’s modulus was determined from the initial slope 
of the resultant stress-strain curves.   
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2.4.4 Particle Fabrication 
Particles were fabricated using the PRINT (particle replication in non-wetting templates) 
process14,15.  PRINT molds for these studies were obtained from Liquidia technologies and 
consisted of a thin layer of a patterned, photocured perfluoropolyether (PFPE) on top of a 
flexible poly(ethyleneterephthalate) (PET) backing.       
To fabricate particles, the pre-polymer mixture was spread onto a mold which was 
adhered to a silicon wafer and chilled to 2-5 °C on a custom built laminator platform.   The 
reduced temperature prevented evaporation of the pre-polymer solution prior to photo-curing.  A 
PET sheet was laminated to the top of the mold and pre-polymer solution, wetting the total mold 
area.  The sheet was peeled away at the nip point of the laminator, leaving the wells of the mold 
filled while wicking away excess solution.  The filled mold was immediately transferred into a 
chilled (~5 °C), nitrogen purged UV oven and cured with UV light (λ =365 nm, 3 minutes, 
power ~ 20 mW/cm2). 
Particles were transferred from the mold by laminating the filled, cured molds to a PET 
sheet which was coated with a thin film of Luvitec (BASF).  The particle-filled mold and Luvitec 
coating were placed in contact and passed through the nip point of a laminator.  To increase the 
yield of harvested particles, a heated laminator was used for this step, with roll temperatures hot 
enough to allow the Luvitec to flow and come into contact with the particles (typically >180 ºF).  
Alternatively, it was possible in some cases to transfer the particles without added heat due to 
“sticky” adhesion of the particles to the Luvitec film.   After cooling briefly, the mold was peeled 
away from the Luvitec sheet at a steep angle, leaving the particles on the Luvitec film in an 
ordered array.   
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Harvesting of the particles from the ordered array on Luvitec into solution was 
accomplished by “bead harvesting”.  In this process, the particles on the harvesting film were 
passed through the vertical nip point formed by two rollers.  At the nip point, a bead of water 
dissolved the Luvitec layer, suspending the particles in solution, as the rollers drew the film 
down through the nip.  The particle solution was then collected using a pipette.   
2.4.5 Particle Harvesting and Purification 
The bead harvesting process leads to well stabilized particles, but leaves an abundance of 
dissolved Luvitec in solution.  The particles were pelleted via centrifugation at 4 ºC (12,000 rpm, 
5-10 minutes depending on particle size) and the supernatant removed carefully so as not to 
disturb the pellet.  The pellet was resuspended in a solution of 0.1% poly(vinyl alcohol) in 
Dulbecco’s pH 7.4 PBS buffer (Fisher Scientific) and this procedure was repeated 2-3 times to 
remove excess Luvitec and any soluble fraction of poly(HPA) or unreacted monomers.   
2.4.6 Particle Characterization 
To accurately determine particle concentration, thermogravimetric analysis (TGA) was 
used.  To determine the weight of salts and polymer in the solution, 50 µL of the particle solution 
was centrifuged exhaustively (14,000 RPM/20 minutes) to pellet the particles.  The supernatant 
(20 µL) was pipetted to a tared TGA pan and the weight was monitored on a Perkin Elmer Pyris 
1 TGA under the following heating steps: 25-115 ºC by 10 ºC/minute followed by a 10 minute 
hold to drive off the water in the solution. The dried sample provided the weight of salts and 
dissolved polymer in solution. In parallel, a 20 µL sample of the particle solution was analyzed 
under identical conditions, with the particle weight determined by subtracting the weight of salts 
and polymer in solution from this final weight.   
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Particles dimensions were determined by analysis of images from a microscope mounted 
camera (Zeiss AxioCam MRm) using a 100x objective (Zeiss Axio Imager D.1M), or by 
dynamic light scattering (DLS) for the 0.78 µm particles using a nano ZS zetasizer (Malvern 
Instruments).  Over 50 fully hydrated particles in pH 7.4 PBS buffer were measured.  Zeta 
potentials for particles were measured on a nano ZS zetasizer (Malvern Instruments) in water.   
2.4.7 Microfluidics  
Microfluidic masters were fabricated in the Chapel Hill analytical and nanofabrication 
laboratory (CHANL) cleanroom.  Chrome on quartz masks were ordered from Benchmark 
Technologies.   SU-8 was coated onto 6 inch wafers with film thickness equal to the desired 
feature height.  The wafers were soft baked at 95 ºC for 90 seconds.  A Karl Suss MA6/BA6 
mask aligner was used to bring the mask into contact with the wafer, followed by 10 second 
exposure time.  Post-exposure bake at 95 ºC  for 2 minutes was followed by soaking in SU-8 
developer for 3 minutes to remove unexposed resist.  The masters were hard baked at 165 ºC for 
30 minutes prior to fabrication of devices.  Feature heights were analyzed using a P-6 
profilimeter (KLA Tencor).   Microfluidic devices were fabricated from silicone (Sylgard 184, 
Dow Corning) sealed to glass after treatment with oxygen plasma.  Flow in the devices was  
driven by a syringe pump at a fixed rate (0.06 µL/min).  Dilute solutions of RBCMs (1-5 µg/mL 
in PBS with 0.1% poly  (vinyl alcohol)) were pumped through the channel and observed with a 
fluorescence microscope (Nikon TE2000).  Videos were taken with a with a Photometrics 
Cascade II:512 camera.  Particle stretching was analyzed with ImageJ software (NIH).   
2.4.8 In vivo Studies 
To track the plasma concentration and biodistribution of particles in mice, 20 mg 
articles/kg mouse weight was administered via a 2.0 mg/mL solution of particles in PBS with 
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0.1% poly(vinyl alcohol) via tail-vein injection to female BALB/c mice of 20-22 g body weight.  
Four mice were examined at each time-point, including points 0.2, 0.5, 1, 3, 7, 24, 56, and 104 
hours post injection.  At each time point examined, mice were sacrificed and tissues harvested.  
Harvested tissues included the lungs, liver, kidneys, spleens, heart and a posterior leg (thigh) 
muscle.  Blood was collected via terminal cardiac puncture.  Control mice were undosed.   
2.4.9 Biodistribution 
The fluorescent signal from the particles in the tissues and blood was measured using an 
IVIS Lumina fluorescent imager (Caliper Life Sciences) with excitation at 675 nm and emission 
measured at 720 nm. Harvested tissues including liver, lung, spleen, kidneys, heart, and 
intestines were weighed, then imaged. Blood was harvested via cardiac puncture, and pipetted in 
100 µL aliquots to black 96 well plates for analysis on the imager.  Control mice without 
injection were sacrificed too and the tissues and blood used as background. The fluorescent 
signal for each tissue sample was background corrected by subtracting the signal from control 
tissues.    Biodistribution profiles for the RBCMs at two hours post-dose were determined by 
percent of recovered fluorescence in the above tissues.  Fluorescent signal in the blood was 
calculated by measuring the fluorescent signal from several aliquots of blood and extrapolating 
to account for the total blood volume in the mice (approximately 1.7 mL/20 g of body weight).   
2.4.10 Pharmacokinetics of Particle Clearance from Blood 
For determination of pharmacokinetic parameters including alpha and beta half-lives, we 
ﬁt the data to a two-compartment model using non-linear regression analysis (Excel). The two-
compartment model assumes that particles are transported between the central and eripheral 
compartments with ﬁrst-order kinetics and that particles re eliminated from the central 
compartment with ﬁrst-order kinetics. The data was fit to Equation 1, where Cp is the 
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concentration of the particle in the plasma, and α and β are rate constants for the distribution and 
elimination processes, respectively.    
                       C  = Ae
-   + Be-                                                       Equation 2.1 
The fit was calculated by nonlinear regression, maximizing the R2 value for the fit and 
producing best fit values for the coefficients and rate constants.  Half-lives for the distribution 
and elimination process were calculated by equations 2.2 and 2.3, respectively.  
                                αt /  =
   . 
 
                                                          Equation 2.2 
                               βt /  =
   . 
 
                                                           Equation 2.3 
AUC (area under the curve) was determined by integrating equation 2.1, which describes 
the plasma concentration/time profile (Equation 2.4).    
                                AUC =
 
 
+
 
 
                                                         Equation 2.4 
The volume of the central compartment, Vc, relates the dose administered and the initial 
particle concentration (equation 2.5).    
                                     V  =
    
   
                                                          Equation 2.5 
Total body clearance, CLT, describes the volume of blood cleared of particles over time, 
and is calculated from the dose administered and the AUC (equation 2.6). 
                                    CL  =
    
   
																																																															Equation	2.6	
The volume of distribution in the elimination phase, Vdβ, describes the volume in which 
the particles would need to be disbursed to provide the observed concentration in blood for the 
elimination phase (equation 2.7). 
                                       Vd  =
   
 
																																																													Equation	2.7	
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2.4.11 Histology 
All tissues were frozen on dry ice shortly after imaging and 5 µm frozen sections 
prepared for staining.  Microscope slides with frozen tissue sections were allowed to thaw at 
room temperature for 20-30 min, at which point they were washed briefly with TBS.  The 
sections were fixed with 2.5 % paraformaldehyde in TBS for 5 min, followed by two 5 minute 
washes with TBS.  The excess paraformaldehyde was quenched with 10 mM ethanolamine in 
PBS for 5 min, followed by washing twice with TBS for 2 minutes.  The sections were 
permeablized with 0.1% Triton X-100 (Alpha Aesar) in TBS for 5 min, and then washed with 
TBS twice for 5 min.  The sections were incubated overnight at 4°C with DAPI (Invitrogen) 
prepared using 0.025 % Tween 20 (Fisher Scientific) in TBS.  Following incubation, the sections 
were washed 4 times for 5 minutes prior to mounting with ProLong Gold antifade reagent 
(Invitrogen).   
All samples were imaged with an Zeiss710 confocal laser scanning microscope with 
filters optimized for the different fluorescent probes, including the DyLight 680 dye in the 
RBCMs.  Images were taken with a 40x objective lens.   
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2.5 Figures 
 
Figure 2.1  Synthetic scheme for hydroxyl PEG acrylates (HPAs).   The structures of the 
monoacrylated products are shown below  the reaction scheme, along  with the naming 
convention. 
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Figure 2.2  Microscopic images of HP3A particles with 0.25 wt% crosslinker in the mold (A), 
transferred on to PVOH (B) and suspended in PBS (C); SEM image of dried particles with 1 wt% 
crosslinker(D). Particles crosslinked with less than 1 wt% PEG4kDA were unable to retain 
integrity in the dry state that they could not be imaged by SEM.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
A B 
C D 
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Figure 2.3  Microfluidic evaluation of HP3A-based RBC mimicking particles. (A) Schematic 
illustration of the microfluidic device used; (B) An image sequence showing 0.25 wt% 
crosslinked RBCM particles (5.4 µm in diameter) squeezing through the 3×3 µm channels (190 
ms between frames). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 2.4  Fluorescent images of the particles used for the in vivo studies.  The particles have 
hydrated diameters of (A) 0.78 µm (B) 3.79 ± 0.17 µm, (C) 6.39 ± 0.56 µm, and (D) 8.88 ± 0.47 
µm.  Scale bars are 20 µm.  The particles were imaged at the DyLight 680 channel. 
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Figure 2.5  Biodistribution of extremely deformable particles of different sizes in mice over the 
course of 5 days.  The total fluorescent signal from the particles in each tissue sampled is shown 
for particles with diameters of (A) 0.78 µm, (B) 3.8 µm, (C) 6.4 µm and (D) 8.9 µm.  Four mice 
were examined per time-point, with error bars representing one standard deviation.   
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Figure 2.6  Biodistribution of extremely deformable particles of different sizes in mice over the 
course of 5 days.  The percentage of the fluorescent signal recovered from the sampled tissues 
was adjusted by the weight of the tissue.  Data is shown for particles with diameters of (A) 0.78 
µm, (B) 3.8 µm, (C) 6.4 µm and (D) 8.9 µm.  Four mice were examined per time-point, with 
error bars representing one standard deviation.   
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Figure 2.7  A plot showing the change in particle concentration in blood over time for 
deformable hydrogel particles of different sizes.  Particles with a diameter of 6.4 µm, similar to 
that of mouse red blood cells, were cleared more slowly and remained in the circulation to a 
greater extent than both larger and smaller particles with identical mechanical properties and 
composition.  The largest of these particles, with hydrated diameters of 8.9 µm, were cleared to 
concentrations in blood below our limits of quantification (indicated by the dashed line).  Each 
data point represents 4 mice, with error bars representing one standard deviation. 
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Figure 2.8   Histological sections of lung, liver and spleen tissue from mice sacrificed 104 hours 
after dosing with (A) 0.78 µm, (B) 3.79 µm, (C) 6.39 µm, and (D) 8.9 µm particles. Images are 
an overlay of fluorescence from DAPI staining (blue) and the Dylight 680 dye that is covalently 
bound to the hydrogel particles (red).  Scale bars are 20 µm. 
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CHAPTER 3: RBC MIMICS WITH HIGH LOADING OF HEMOGLOBIN 
 
3.1 Introduction 
The three major hurdles that impede application of HBOCs are: (1) renal toxicity1 from 
hemoglobin dissociation; (2) vasoactivity2 and (3) limited circulation time. While some of the 
first and second generations of RBC substitutes based on derivatized Hb could avoid renal 
toxicity, the circulation times were usually not long, and vasoactivity still remained because of 
interaction between nitric oxide and hemoglobin molecules.  
Nitric oxide (NO) is a tiny molecule closely involved in many physiological functions, 
including but not limited to, blood vessel dilation,3 modulation of leukocyte adhesion4, and 
neurotransmission5. NO is produced in endothelial cells lining blood vessels, and normally 
targets the guanylate cyclase in the smooth muscle of blood vessels, leading to relaxation. In the 
vascular lumen, NO molecules have to traverse a significant distance across several diffusion 
barriers before reaching RBC: the ‘RBC-free zone’ adjacent to the vessel wall during blood flow, 
the unstirred plasma layer around an RBC, and the membrane of RBC. Therefore, reaction of Hb 
within RBCs is minimized and vasoconstriction prevented.6,7 Cell-free Hb, however, is not 
affected by intravascular flow due to its small size, and can therefore reach the site of NO 
production to consume NO, leading to vasoconstriction. This is why most of the early 
generations of RBC substitutes caused hypertension because the size of the carriers, either single 
or polymerized Hb, was too small.  Therefore, increasing the hydrodynamic size of the carrier 
may help minimize vasoconstriction. 
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Encapsulating Hb within a carrier to mimic the cellular structure, can not only increase 
the hydrodynamic size, but also increase the diffusion barrier for NO, and is therefore being 
explored as a potent alternative to RBC substitutes based on Hb. 
The idea to mimic the cellular structure using synthetic particles dates back to the 1950s, 
when Thomas Chang first described artificial RBCs with synthetic membranes  encapsulating Hb 
and enzymes.8 This RBC mimic had an oxygen-dissociation curve comparable to that of true 
RBC; however, the size of the particles was in the range of 1 to 100 µm and could not be well 
regulated. The extreme difficulty in controlling particle size in these early days hampered further 
studies of these carriers because of possible blood flow issues in the capillaries. Biocompatibility 
was also a concern for these synthetic polymer membranes. 
Recent years have witness increasing research on employing nanocarriers as RBC mimics 
by incorporating hemoglobin inside, probably as a result of the progress in nanotechnology. 
These new systems are considered as third-generation RBC substitutes. Liposomes (or vesicles) 
with sizes around 200 nm or smaller have been extensively used as RBC mimics ever since the 
1980s because of technical advances in liposome formulation.9,10 Hb and other enzymes could be 
encapsulated within the lipid membranes, which better mimicked RBC surface than synthetic 
polymer membranes. These liposome-based HBOCs, termed as Hb-vesicles (HbVs), were found 
to remain longer in circulation than the earlier reported large artificial RBCs. Many groups have 
carried out research to further improve the circulation time of HbVs, and modification of surface 
was found to be effective when PEG-lipid was used to formulate the liposomes. Eishun 
Tsuchida’s group had carried out many thorough studies on the tests of these HbVs, including 
biochemical characterization of hemoglobin inside the vesicles, and investigation of circulation, 
metabolism of the vesicles.11–13 
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Alternative to HbVs, polymersomes14,15 and micelles16 have also been fabricated as RBC 
mimics. Similar to HbVs where lipids self-assembled to form liposomes, polymersomes and 
micelles were formed by the self-assembly of amphiphilic polymers. Palmer’s group used 
diblock copolymer of PEG and poly(butadiene) (PBD) to formulate polymersomes. Polydisperse 
Hb-containing liposomes were extruded through polycarbonate membrane with pore size of 
either 100 or 200 nm, and monodisperse liposomes were formed. They also used diblock 
copolymer of PEG with either Poly(L-lactic acid) (PLA) or poly(ε-caprolactone) (PCL) to 
generate polymersomes because PLA and PCL are biodegradable. Jing’s group used a triblock 
copolymer to produce micelles and encapsulated Hb inside. Rather than mixing Hb with the 
polymer to physically encapsulate Hb, they used click chemistry to covalently link Hb into one 
block of the polymer. 15 
Biodegradable polymers have also been used to form porous particles encapsulating Hb. 
Double-emulsion techniques were generally used in these studies to form nanoparticles with 
hollow interiors where Hb was loaded. The size of these particles is similar to that of HbVs and 
they could circulate in blood, though not long enough. To increase the biocompatibility, stability, 
and to extend circulation time of the nanoparticles, block copolymers of these thermoplastics 
with PEG were also used to fabricate nanoparticles with PEG on the surface.17,18 Although 
oxygen binding properties of the encapsulated Hb were not affected, it took longer times to 
saturate Hb within the particles and to deliver oxygen because of the shell thickness in the 
particles.  
Hydrogels are promising biomaterials extensively explored in both tissue engineering and 
drug delivery because of their hydrophilicity and biocompatibility.19 Hydrogels with submicron 
sizes, named nanogels, have also been used as RBC mimics.20,21 In Palmer’s work, acrylamide 
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monomers were polymerized within liposomes to form monodispersed nanogels after removal of 
the lipids. Once Hb was loaded into the liposomes with monomers, polymerization of the 
monomers could retain Hb inside probably due to chain transfer of monomer radicals to the 
protein. An obvious advantage of using nanogels as RBC mimics is the rapid gas exchanged rate 
through the particles because of the high water content, and this is also why our RBC mimics 
based on PRINT hydrogels are attractive as oxygen carriers. 
To extend our mimicry of RBCs, the RBC-sized deformable particles discussed earlier 
were loaded with bovine hemoglobin. The low mesh density allowed Hb molecules to diffuse 
into the interior of the particles. Carboxyl group from CEA was used as a reacting handles to be 
conjugated with lysines of hemoglobin. Similar conjugation of Hb to poly(acrylic acid) had been 
carried out before and was found to cause no adverse effect on the structure and function of the 
protein.22 
3.2 Results and Discussion 
3.2.1 Fabrication and characterization of blank particles 
To maximize the potential of soft particles for long circulation times, we used only 0.05 
wt% PEG4kDA in particle formulation as in Table 2.2C, resulting in hydrogels with a modulus 
of 6.5 kPa. Elastomeric fluoropolymer molds with patterned wells of 2 µm in diameter, 0.6 µm 
in height, were used to fabricate particles crosslinked with 0.05 wt% PEG4kDA. Figure 3.1A 
shows particles with polymerized Rhodamine dye confined in the mold. Once transferred out of 
the mold and suspended in PBS, the particles hydrated and swelled to 6.3 µm in diameter and 1.8 
µm in height (Figure 3.1B), with ζ-potential of of -23 mV in 0.1X PBS.  
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3.2.2 Conjugation of Hb into the RBCM particles 
To avoid the complications of allosteric effectors such as 2,3-diphosphoglycerate, which 
are required for the native operation of human Hb23, we  used bovine Hb. Bovine Hb only 
requires chloride ion for native operation,24  which can be provided by buffers like PBS and is 
present in the blood. The conjugation of bovine Hb to the particles was carried out using 
EDC/sulfo-NHS chemistry to couple carboxylic acids in the particles to amines of the lysines of 
Hb25 (Figure 3.2). In the first step, carboxyl groups in the particles were activated by EDC/sulfo-
NHS in 0.1 M MES buffer with pH = 4.5. Then the activated particles were transferred to PBS 
(pH = 7.4) after removing excess EDC and sulfo-NHS. Bovine Hb was added to react with the 
amine-reactive NHS esters in the particles. A low concentration of particles (1 mg/mL) was 
employed during reaction to avoid inter-particle crosslinking by Hb to form larger aggregates. 
Sulfo-NHS was also used to maintain the negative charge of the particles, helping to avoid 
aggregation.  
We confirmed that Hb had indeed reacted with the particles by directly observing the 
particles conjugated with dye-labeled Hb under a fluorescent microscope. Both Fluorescein and 
Rhodamine labeled bovine Hb were synthesized using the corresponding dye-NHS to react with 
Hb at a molar ratio of 15:1. Excess dye-NHS was used to ensure Hb molecules were labeled with 
several dye molecules per protein. There are 42 lysine amino groups on the surface of a single 
Hb molecule26; therefore, the dye-labeled Hb possessed multiple unfunctionalized amine groups 
for use in coupling to the particles. After reacting with dye-free particles through the EDC/sulfo-
NHS coupling method, the resulting particles obtained fluorescence arising from the dye-labeled 
Hb (Figure 3.3A, B).  
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To determine whether the dye-Hb was covalently conjugated to the RBCMs or more 
loosely associated via non-covalent interactions, we fabricated Fluorescein-labeled particles by 
copolymerizing Fluorescein-o-acrylate into the polymer network (Figure 3.3C). We incubated 
the particles with Rhodamine-tagged Hb (Rh-Hb) in PBS overnight, then pelleted and washed 3 
times to remove unassociated protein. The washed particles had no fluorescence in the 
Rhodamine channel under a fluorescent microscope, indicating a lack of non-specific binding of 
Hb to the RBCMs. Considering that Hb acquires slightly negative charge at pH = 7.4 (pI = 6.8)27, 
a lack of electrostatically driven association with negatively charged particles is reasonable. In 
contrast, when the particles were first activated by EDC/sulfo-NHS and then incubated with Rh-
Hb followed by washing, they displayed red fluorescence from the covalently conjugated Rh-Hb 
(Figure 3.3D). The red fluorescence from Rhodamine overlapped perfectly with the green 
fluorescence from Fluorescein (Figure 3.3E). The covalent conjugation of Hb into the RBCM 
particles was also confirmed by FTIR spectroscopy (Figure 3.3F). The peaks at 1650 and 1550 
cm-1 corresponding to the amide I and amide II region of hemoglobin28 were also present in the 
spectrum of the Hb-RBCM particles, which were thoroughly washed to remove unassociated  
Hb. The peak at 1579 cm-1, characteristic of the carboxylate moiety that was consumed by the 
conjugation chemistry29, was attenuated in the Hb-RBCM particle sample, indicating a decrease 
in the prevalence of this functionality as a result of conjugation to Hb. Combining the 
spectroscopic result from FTIR and the microscopic observations, we concluded that Hb was 
covalently conjugated to the hydrogel matrix of RBCM particles.  
Besides Hb, other proteins bearing lysine groups on the surface could possibly also be 
conjugated into the particles. We used Alexa Fluor® 488 (AF488) labeled bovine serum albumin 
(BSA) as a representative protein to demonstrate this. By incubating AF488-BSA with activated 
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dyeless particles, the resulting particles gained fluorescence from AF488 (Figure 3.4), indicating 
covalent conjugation of BSA to the particles. 
3.2.3 Confocal studies of the Hb-RBCM particles 
While the free volume fraction was very high in the particles due to the low mesh density 
and high water content, we wanted to determine if the protein was distributed throughout the 
bulk of the particles or limited to the surface.  For these experiments, we made larger (18 µm tall, 
18 µm diameter cylinders) hydrogel particles with identical composition to facilitate confocal 
imaging analysis. These large model particles, which were fabricated without the inclusion of a 
fluorescent dye, were allowed to react with Fluorescein-Hb under the same conditions as 
discussed above. Confocal laser scanning microscopy (CLSM) was used to scan the particles at 
various cross sections due to the narrow depth of focus of this technique. We randomly selected 
a representative particle and collected a stack of scans in the xy plane while varying the focal 
depth in the z direction to cover the entire particle. All of the xy scans obtained showed 
fluorescence associated with the covalent attachment of fluorescein-Hb to the particle matrix, 
indicating that Hb had been distributed throughout the particle interior. A reconstructed 3D view 
of the model particles is shown in Figure 3.5, with orthogonal cross-section views of the 
representative particle. Although the particles used for the confocal experiments were larger than 
the ~6 µm RBCMs, they were polymerized under the same condition with identical compositions 
and it is reasonable assumption that the mesh size, which depends on crosslinker density, in both 
sets of particles were similar.  
3.2.4 Hb loading efficiency of RBCM particles 
By varying the initial Hb concentration for the conjugation, the loading ratio of Hb into 
the RBCM particles could be adjusted. We define the weight ratio of conjugated Hb to the 
 60 
polymer network of particle as the loading ratio, R. The maximum theoretical value of R would 
be greater than 60 for the case of every carboxyl group in the particles being conjugated to one 
Hb molecule. While steric effects make saturation unlikely, we observed that very high loading 
resulted in the undesirable effects of particle aggregation and sedimentation. Loading ratios as 
high as 5.1 were obtained without any observable aggregation or sedimentation effects. The 
loading ratio was changed by varying the amount of Hb added to a fixed amount of carboxyl-
activated particles (1mg/ml; Figure 3.6A).  The amount of Hb loaded into the particles was 
determined by measuring depletion of free protein in the supernatant solution by UV-vis 
spectroscopy through adaption of the standard cyanometHb method21.  The encapsulation 
efficiency for these particles was defined as the amount of the Hb loaded into particles divided 
by the overall starting amount of Hb. Generally, incubation of particles with higher 
concentrations of Hb led to increased R and decreased encapsulation efficiency.  The highest 
stable loading achieved, with R = 5.1, resulted in an encapsulation efficiency reduced to 50%. 
Although the encapsulation efficiency was not very high for higher Hb loadings, unbound Hb 
could be collected from the particles and reused for conjugation. The size of the particles 
decreased slightly with increased Hb loading (Figure 3.6B). 
High loading of Hb into oxygen carriers is desirable for blood substitutes, which would 
require large doses administered with high concentration of Hb to have oxygen carrying capacity 
similar to that of blood. The high Hb concentration in normal blood (14 g/dL) has been 
approached by some HOBCs (5~10 g/dL1). The weight ratio of Hb to the lipids (as in liposomes) 
or polymers (in polymersomes) used to constitute those carriers, similar to R defined above, has 
varied widely in different cases, from 0.3 to 9.36.30 The values of R here arose from RBCM 
particles that were composed of only 10% of a monomer capable of conjugation to Hb (CEA). It 
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is possible that even higher loading ratios could be obtained when the amount of CEA in the 
particles is increased.  
3.2.5 CD and UV-vis spectroscopic study 
Retention of the structure and activity of the encapsulated Hb is a crucial consideration 
for the application of this protein towards carrying oxygen.  The secondary structure of proteins 
is essential to their function; retention of this structure can be used to infer protein activity31. 
Protein secondary structure can be monitored by far UV-CD spectroscopy32. We measured the 
UV-CD spectra, in the range of 185 to 260 nm, for Hb conjugated to RBCM particles, a mixture 
of particles and free Hb, and unmodified free Hb in identical buffer conditions to look for 
structural changes in the protein (Figure 3.7A).  
The strong maximum at 194 nm and double minima at 208 and 222 nm in the CD 
spectrum of free Hb (Figure 3.7A), are characteristics of α–helix22. The CD spectrum of the 
suspension of particles mixed with free Hb (Hb+particles) was very similar to the spectrum of 
free Hb, with the peak at 194 nm slightly decreased in intensity. For Hb conjugated to the 
particles (Hb-c-particles), the peak positions were the same, with slightly decreased intensity at 
208 nm, and dropped larger dip in intensity at 194 nm. When the sample of Hb-c-particles was 
half diluted and subjected to CD study, the obtained spectrum also crossed over the same point 
(Figure 3.7A). So the percentage helicity of Hb in the particles could be assessed by comparing 
the ellipticity at 222 nm33.  As the minimum at 222 nm for Hb-c-particles only shows minor 
different from that of free Hb, we can conclude that the percentage helicity of Hb conjugated to 
particles was close to native Hb, indicating negligible change in the secondary structure of Hb-c-
particles. 
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Although it has been reported that secondary structure of Hb could be changed when 
interacting with nanoparticles due to hydrophobic interactions or changes in ionic strength near 
the particles28,34, we do not anticipate this effect in our case as the microgels are very soft and 
hydrophilic, and the large pores in the particles allowed the ions of PBS to diffuse into the 
interiors fairly easily to maintain uniform ionic strength. In a recent study where bovine Hb was 
conjugated to high molecular weight poly(acrylic acid) using similar coupling chemistry, the 
authors observed the secondary structure of Hb to be unchanged22.   
The Soret CD of Hb, arising from the interaction between π-π* transition of the heme 
groups and the surrounding aromatic amino acids, is greatly influenced by the orientation and 
position of the aromatic amino acid residues35,36. Changes in the Soret CD of Hb can be an 
indication of differences in the heme environment as well as the electronic state of the heme. The 
Soret CD of Hb, Hb+particles, and Hb-c-particles were recorded in the wavelength range of 350 
to 450 nm in Figure 3.7B. Comparing the three spectra in Figure 3.7B, the peak positions at 416 
nm remained unchanged, implying that the heme environment was well preserved in the 
conjugated Hb compared to the starting Hb. The reduction in the peak intensity was most likely 
caused by light scattering37. The electronic state of heme was in the oxidized form for all three 
samples as the starting Hb had mostly been automatically oxidized into metHb, which is unable 
to bind oxygen. 
To obtain Hb-RBCM particles capable of binding oxygen with low metHb, the 
suspension of Hb-RBCM particles was added with reducing agents. Sodium dithionite (10 molar 
equivalents to total Hb concentration) was first added to reduce metHb back to deoxyHb, and 
excess dithionite was removed by spinning down the particles and decanting for 3 times. Then 
ascorbic acid (10 mM) was added to the suspension for long term reduction. Sodium dithionite is 
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very efficient in reducing metHb back to deoxyHb; however, excess dithionite may be oxidized 
by residual oxygen in solution to generate reactive oxygen species (ROS) that in return would 
accelerate the oxidation of Hb38. Figure 3.7C shows the UV-vis spectra of Hb-particle (R = 2.8) 
suspension. The as prepared particle suspension showed a Soret peak at 405 nm, characteristic of 
metHb. After reducing iron(III) back to iron(II) by dithionite, the Soret peak moved to 430 nm, 
characteristic of deoxyHb39. Carbon monoxide could bind to deoxyHb in the particles to shift the 
Soret peak to 419 nm16. To the carbonized Hb-particle suspension, air was bubbled for 20 min 
under light and the spectrum of the resulting suspension showed a Soret peak at 412 nm, 
characteristic of oxyhemoglobin, along with two feature peaks at 542, 576 nm40. 
An indirect method was used to estimate the metHb level in the particles. Generally, the 
difference in absorbance at 540 nm of a hemoglobin-containing solution before and after 
addition of KCN can be used to calculate the metHb concentration using UV-vis spectroscopy21. 
Since the absorbance at 540 nm is much lower than that at the Soret peak, accurate measurement 
would require higher concentration of Hb (therefore higher particle concentration) than that used 
for the UV-vis spectra in Figure 3.7C. However, higher concentration of particles would cause 
more light scattering that interfered with the absorbance measurement. To circumvent this 
problem, we polymerized HP3A with 10 wt% CEA and 1 wt% initiator, but without crosslinker 
to make un-crosslinked polymer that could represent the formulation of the particles. The 
resulting polymer (Mn = 41 kDa, Mw = 233 kDa) was conjugated with Hb to generate 
poly(HP3A-co-CEA)-Hb conjugate, in which the loading ratio was 0.8 (high loading ratio would 
result in polymer precipitation). The poly(HP3A-co-CEA)-Hb conjugate was reduced by sodium 
dithionite, and excess dithionite was removed. Ascorbic acid (10 mM) was added to the resulting 
solution with [Hb] = 5 mg/mL. For as prepared, un-reduced Hb-polymer solution, the metHb 
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level is 75 %, similar to the metHb level (69 %) in the stock solution of Hb. The metHb level 
immediately after the reduction dropped to 1.4 %. The solution was kept under aerobic 
condition, and the metHb formation over time was measured over 1 month as summarized in 
Figure 3.7D. After 1 month, the metHb level rose to 25 %, and within 10 days the metHb did not 
exceed 10 %. 
3.2.6 Oxygen dissociation and NO oxidation kinetics 
We used a stopped-flow spectroscopy to study the kinetics of oxygen dissociation and 
NO induced oxidation of oxyHb following established methods.41–43 Both free Hb and Hb-
RBCM were saturated with oxygen before measurement. By quickly mixing 0.5 µM free Hb 
(thus 2 µM heme) or Hb-RBCM (R = 0.9, with the same Hb concentration), with 0.9 mM sodium 
dithionite, the absorbance change at 436 nm was recorded to monitor the decrease of oxyHb. 
Since light scattering from particles also contributed to absorbance, the absorbance change was 
normalized to plot the change versus time, as shown in Figure 3.8A. The oxygen dissociation 
rate for Hb in Hb-RBCM was almost 2 fold slower than that of free Hb. 
NO induced oxidation of oxyHb was studied by measuring the absorbance change at 419 
nm after quickly mixing 0.5 µM free Hb or Hb-RBCM with 14 µM NO solution. The absorbance 
change was normalized to plot the change versus time, as shown in Figure 3.8B. At the 
concentrations used, NO was in excess so that the kinetics could be regarded as pseudo-first-
order. By fitting the curves, the calculated rate constants were 18 and 7.4 μM-  ∙ s-  for free Hb 
and Hb-RBCM, respectively. The former agrees very well with literature value around 20 
μM-  ∙ s-  [65], indicating high measurement fidelity. The rate constant of Hb-RBCM is 2.5-fold 
less than that of free Hb, probably from slowed diffusion secondary to the gel structure of the 
RBCM.  
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3.2.7 Mechanical and fluidic properties of Hb-RBCM particles 
The RBCM particles were fabricated from a low modulus material to take advantage of 
the increased circulation times seen with such highly deformable RBC-like microgels44.  
However, it stands to reason that the cargo loaded into these gels (Hb) could increase the 
modulus of the resultant gels.  To test the effect of loading these gels with Hb on the elastic 
modulus, we incubated bulk polymer samples with Hb and carried out the conjugation under 
identical conditions used for Hb conjugation to particles.  At low loading of Hb, this strategy 
seemed to be effective; the modulus of bulk samples with loading ratio of 0.38 increased 
somewhat compared to Hb-free polymer gel, with E = 9.1 kPa and 6.5 kPa, respectively.  
However, higher loadings of Hb could not be obtained, likely as a result of the vastly reduced 
surface area to volume ratio in the bulk samples compared to the microparticles. The diffusion-
limited conjugation reaction was likely much slower in the bulk samples, leading to hydrolysis of 
the reactive NHS ester before reaction could proceed fully.  
To directly evaluate the deformability of the Hb loaded particles, the same microfluidic 
device as in Figure 2.3 was used. Dilute suspensions of particles were flowed through the 
devices via a syringe pump at a constant rate of 60 µL/min. The Rhodamine dye labeled particles 
could be tracked as they traveled through the channel of the microfluidic device using an 
inverted fluorescent microscope focused on restrictions close to the outlet of the channel. We 
found that moderate (R ≤ 2.8) loading of Hb had no noticeable effect on the ability of the 
particles to deform to elongated shape and navigate the pores (see image sequence in Figure 
3.9A). The shape change of the particles was reversible as after coming out of the pores they 
could return to the original disc shape. However, when the R increased to 5.1, the majority of the 
stiffer particles became lodged in the entrances to the pores (Figure 3.9B), although a minor 
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fraction of the particles could still pass through. Therefore, with a loading ratio of Hb as high as 
2.8, the RBCM particles were still very deformable. 
A high concentration of Hb in a HBOC fluid is necessary to fulfill oxygen transport 
targets. We could concentrate the Hb-RBCM particles by centrifugation in order to increase the 
overall Hb concentration. However, a fluid packed with very high density of Hb-RBCM particles 
may become very viscous, and hence is inappropriate for transfusion. To mimic the hematocrit 
(i.e., packed cell volume fraction) of blood (40-45%), we spun down particles and decanted to 
obtain a pellet with a volume fraction around 40%. While the fluid with particles whose R = 2.8 
became quite viscous at this packed particle volume fraction (PPVF), particles with R = 1.3 
could flow easily at the same PPVF with the overall Hb concentration in the suspension to be 5.2 
g/dL. The viscosity of this fluid was evaluated using a rheometer that could control the shear rate 
and measure the corresponding shear stress and viscosity. As a control, collected mouse blood 
(in heparinized tube to avoid clotting) was also subjected to the rheometer. By ramping the shear 
rate from 0.1 to 1,000 1/s, covering the shear rates found in blood flow45, the rheological 
properties of the Hb-particle suspension and mouse blood were compared as in Figure 3.9C, D. 
As can be seen, over different shear rate ranges, the shear stress and viscosity of the Hb-RBCM 
fluid was mostly lower than the blood from two mice. The Hb-RBCM fluid displayed rapid 
decrease in viscosity leading to a local maximum in the stress, which may indicate phase 
separation and formation of shear band46,47. This behavior will be investigated in future work. 
To test if the particles can survive at high shear rate, the same suspension (R=1.3, [Hb] = 
5.2 g/dL) was sheared on the rheometer at a constant rate of 1,000 1/s for 10 min, and the 
resulting suspension was observed under optical microscopy to check the integrity of the 
particles. The particles were indeed intact after shear as shown in Figure 3.9E. When the 
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suspension was spun down, the supernatant was completely colorless, indicating no release of 
dye or Hb because of particle breakdown.  
3.2.8 Cytotoxicity of the RBCM particles 
Human vascular endothelial cells (HUVEC) and HeLa cells were chosen as in vitro 
models to assess the cytotoxicity of the RBCM particles. To investigate the possible effect of 
CEA on cytotoxicity, RBCM particles with even higher content of CEA (20 and 50 wt%) were 
also fabricated following similar procedure for the 10 wt% CEA particles, and were dosed to the 
cells.  Hb-RBCM particles (R=2.8) with and without reduction of metHb were also dosed to both 
cell lines. To ensure similar numbers of Hb-particles dosed to the cells, the concentration of the 
Hb-particle suspensions were calculated based on the weight of polymers only, excluding Hb. 
After incubation the cells with different particles for 72 h, the cell viability was quantified by 
MTS assay. The results in Figure 3.10 show that, for both cell lines, unloaded particles had 
minimal cytotoxicity, although with more CEA the cell viability was slightly lower. Unreduced 
Hb-RBCM particles showed cytotoxicity to both cell lines, probably because of the oxidative 
stress from metHb in the particles48. For reduced Hb-RBCM particles, in the lower dose range, 
there is little cytotoxicity, while at higher dose, the viability of the cells decreased with 
increasing particle concentration, possibly due to higher metHb formed in the cell culture. 
Therefore, for our goal to increase the loading of Hb into RBCM particles by charging particles 
with more CEA, the biocompatibility issue of the resulting particles would rely less on CEA, but 
more on the metHb level in the particles. We already started to investigate incorporating ROS 
scavenging enzymes to solve this issue for future application. 
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3.2.9 Conclusions and Future Work 
Here we have demonstrated the synthesis of RBC-like hydrogel microparticles that retain 
their deformability with covalently bound Hb, which retained native secondary structure, 
homogeneously distributed throughout the particle matrix.  The particles could be loaded with 
over 70 wt% Hb (loading ratio R = 2.8) and the metHb level under aerobic condition could be 
controlled to be less than 10 % within 10 days.  We demonstrated that Hb in the particles could 
bind oxygen when carbonized Hb in the particles was purged with air.  
Given that hemoglobin, a 64 kDa protein (~8 nm in hydrodynamic diameter), uniformly 
distributes throughout the lightly crosslinked RBCM particles, we can infer a large pore size for 
these particles. Therefore, reducing agents like ascorbic acid may only work when the particle 
fluid is stored, while not work effectively after injection of the fluid. Instead, larger enzymes 
which act on Hb found in RBCs to regulate metHb level, such as superoxide dismutase (SOD) 
and catalase (CAT) may be conjugated to the particles through the same conjugation chemistry, 
but at much lower concentration.  Chang, et al. polymerized SOD, CAT with Hb to obtain 
polyHb-SOD-CAT using glutaraldehyde, which prevented problems related to oxidation of Hb49.  
Inclusion of low amount of these enzymes into the particles may be efficacious in scavenging 
ROS, resulting in low level of metHb over a long time even under aerobic conditions. 
While added Hb could act as crosslinker to shrink the particles and increase the modulus, 
this effect was not observed to be dramatic except for cases with very high loading of Hb.  This 
may be due to inclusion of Hb without the formation of crosslinks because of a low density of 
reactive sites on the RBCM particle.  Hb-RBCM particles (R = 1.3) could also survive high shear 
rate (up to 1,000 1/s) as the particle remained intact after the suspension with 5.2 g/dL Hb was 
sheared for 10 min. 
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The method of protein loading reported here should be general with respect to other 
proteins of similar or smaller size to Hb due to the ubiquitous presence of the lysine residues 
essential to the conjugation reaction, as BSA was also successfully loaded into the particles. 
Advantageously, the loading of a protein to the RBCM particle matrix were both carried out in 
aqueous conditions, avoiding potential solvent based denaturation of protein50.  For example, 
butyrylcholinesterase, a native protein that can degrade nerve agents, may be conjugated to the 
particles to synthesize nerve agent scavenger that may take effect over extend times. 
3.3 Experimental Section 
3.3.1 Materials  
Acryloyl chloride, triethylene glycol, CEA, 1-hydroxycyclohexyl phenyl ketone (HCPK), 
fluorescein-o-acrylate, bovine Hb, Dulbecco’s phosphate buffer saline (PBS), potassium cyanide 
(KCN) and potassium ferricyanide (K3Fe(CN)6), sodium dithionite, ascorbic acid, carbon 
monoxide, were all received from Sigma-Aldrich. Polyethylene glycol (MW=4,000 g/mol) 
diacrylate (PEG4kDA), methacryloxyethylthiocarbamoyl rhodamine B (PolyFluor® 570) were 
from Polysciences, Inc. Sulfo-N-Hydroxysuccinimide (NHS), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC), Fluorescein-NHS, Rhodamine-NHS, 
AF488-BSA and 2-(N-morpholino) ethanesulfonic acid (MES) buffer were all received from 
Thermo Scientific.  Perfluropolyether molds were received from Liquidia Technologies. 
Sylgard® 184 for making microfluidic devices was from Dow Corning. DI water was used and 
all the other organic solvents were received from Fisher Scientific.  
3.3.2 Synthesis of dye-labeled Hb 
To 1 mL Hb solution (20 mg/mL) in borate buffer (pH=8.5), 220 µL DMF solution of 
fluorescein-NHS or rhodamine-NHS (10 mg/mL) was added and allowed to react at RT for 1 h. 
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The resulting solution was transferred to Slide-A-Lyzer dialysis units (Thermo Scientific) with a 
cut-off size of 20 kDa. The dye-labeled Hb solution was dialyzed against 1L DI water for 12 h 
(water changed twice) to completely remove the excess dye-NHS. The purified dye-Hb solution 
was collected into an eppendorf  tube covered by aluminum foil and stored at 4 °C before use.  
3.3.3 Synthesis of poly(HP3A-co-CEA) 
A mixture of HP3A (899 mg) and CEA (100 mg) with 1% HCPK (1 mg) was purged 
with nitrogen for 15 min. Deoxygenated methanol (6 mL) was added to the monomer mixture to 
obtain a homogenous solution. The solution was irradiated by UV light (λ=365 nm, power =20 
mW∕cm2) for 8 min under nitrogen purge. After curing, water was added to the polymer solution 
and dialyzed using a Slide-A-Lyzer dialysis unit with a cut-off size of 3 kDa. The dialyzed 
polymer solution was lyophilized to weigh the dry sample. About 5 mg of the dry polymer was 
dissolved in 1 mL filtered DMF and subjected to GPC (Waters) analysis on the molecular weight 
using PEO standard. 
3.3.4 Modulus Testing 
Refer to 2.4.3.  
3.3.5 Particle fabrication and characterization 
Refer to 2.4.4 and 2.4.5.  
3.3.6 Protein Conjugation to particles and polymers 
In a typical reaction of Hb to particles: to 0.4 mg particles suspended in 0.5 mL MES 
buffer (pH = 4.5) was added with 100 μL EDC solution in MES (0.7 mg/mL) and 100 μL sulfo-
NHS solution in MES (2 mg/mL). The resulting suspension was allowed to shake at RT for 20 
min. Then the particles were spun down at 10,000 g centrifugation and washed for 3 times with 
PBS to remove excess EDC, sulfo-NHS. The particles were resuspended into 200 µL PBS; to 
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this suspension, different amounts of Hb (from 0.2 mg to 4 mg) were added and the final volume 
of reaction was remained at 0.4 mL. The conjugation continued for 12 h at 4 °C in a shaker 
(Eppendorf) at 1,000 rpm. After the reaction, the resulting Hb-particles were washed 3 times in 
PBS and resuspended into 0.4 mL PBS for future characterizations. Dye-labeled Hb and AF488-
BSA were conjugated to the particles following a similar protocol. To calculate the loading ratio 
of BSA, a Coomassie assay was used to measure the depletion of BSA in the solution after 
conjugation with the particles.  
To conjugate Hb to poly(HP3A-co-CEA), the polymer was dissolved in MES buffer and 
added with EDC, sulfo-NHS similarly to the above procedure for particles. After activation for 
20 min at RT, the solution was added with PBS and filtered using a centrifugal filtering device 
(cut-off size = 3k Da; Millipore) to quickly remove excess EDC/NHS, and increase the pH to 
7.4. To the resulting solution containing 1 mg/mL polymer, Hb (2 mg/mL) was added and the 
reaction continued for 6 h at 4 °C. After the reaction, the solution was purified using a 
centrifugal filtering device with cut-off size of 100 kDa to remove un-conjugated Hb. 
3.3.7 CSLM study of model particles  
CLSM images were collected with an Olympus FV 500 microscope with filters optimized 
for fluorescein dye in the RBCMs. Images were taken using a 60X oil objective lens. Confocal 
sections were collected in the image scan x-y-z mode. A single particle that was vertically 
standing on the slide was chosen. By focusing both the bottom and top of that particle, the 
starting and ending focus positions were selected with an increment of 0.414 µm. The scanning 
of the sections generated a series of images, which were reconstructed into a 3D view using the 
software MetaMorph®. 
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3.3.8 Reduction of metHb and Hb binding to CO and oxygen 
To Hb-particle suspension in PBS, the particles were spun down and resuspended in 
deoxygenated PBS (deoxy-PBS: PBS purged with Argon for 30 min). Sodium dithionite (10 
equivalent molar ratio to Hb) dissolved in deoxy-PBS was added to the particle suspension, and 
the reduction continued at RT for 5 min. Excess dithionite was removed by spinning down 
particles and washing with deoxy-PBS 3 times, followed by addition of ascorbic acid (10 mM). 
CO was purged to reduced Hb-particle suspension to convert deoxyHb to CO-Hb with the 
suspension in a tube covered by aluminum foil. When CO-Hb-particle suspension was purged 
with air for 20 min under light, oxygen could replace CO to bind Hb.  
3.3.9 UV-vis spectroscopy of Hb and Hb-RBCM particles 
The UV-vis spectra were measured on a Cary-50 UV-vis spectrometer in the wavelength 
range of 200 nm to 800 nm. The scan rate was 300 nm/min with 0.5 nm interval. PBS solution 
was used as the background and subtracted. For the determination of total Hb concentration in 
solution, a standard curve of cyanmethemoglobin was obtained by measuring the absorbance of 
the cyanmetHb solution at 540 nm with concentrations of 0.05, 0.1, 0.2, 0.4 and 0.8 mg/mL. The 
metHb level was measured by adding 15 µL KCN (10 wt% solution) to the Hb containing 
solutions/suspensions (1 mL) and the difference in the absorbance at 540 nm before and after 
addition of KCN was used to calculate the metHb concentration21. To test the metHb formation 
over time, the reduced Hb-polymer solution was dispensed as 1 mL aliquots into multiple Falcon 
tubes (50 mL) with the top of solution filled with air in the tubes. The concentration of the 
particles used for the UV-vis spectroscopy was only 0.05 mg/mL, with Hb concentration of 0.14 
mg/mL to ensure absorbance lower than 1. With the low concentration used, light scattering 
became minimal. 
 73 
3.3.10 Circular Dichroism (CD) spectroscopy studies 
The CD spectra of unmodified Hb, Hb physically mixed with RBCM particles and Hb-
RBCM particles were recorded using a Chirascan Plus CD spectrometer (Applied Photophysics, 
Inc.) at 23 °C.  Each sample was diluted in 10 mM K2HPO4 buffer (pH=7.2; K2HPO4 buffer 
was used to avoid the absorbance below 200 nm associated with the chloride in PBS), and the 
buffer spectrum was subtracted. The step resolution was kept at 0.5 nm/data point, and the 
bandwidth and sensitivity were 1 nm and 20 millidegrees respectively. Particles lightly loaded 
with Hb (R=0.4) were used for the CD study because higher Hb loading resulted in increased 
light scattering that interfered with the measurement51. For the determination of secondary 
structure change, the samples were diluted to contain 0.16 mg/mL Hb, and particle concentration 
maintained at 0.4 mg/mL where applicable. The samples were scanned from 190 to 260 nm, the 
scan speed was maintained at 50 nm/min. To record the Soret CD bands, each sample contained 
1mg/mL Hb and scanned from 350 to 450 nm at a scan speed of 50 nm/min, a path length of 1 
mm, and eight accumulations. The higher concentration of Hb (1 mg/mL) was used for the Soret 
CD spectra because the absorbance of Hb in this wavelength range is much weaker than that in 
far UV. 
3.3.11 Stopped-Flow Spectroscopy 
A stopped-flow, rapid mixing instrument (Applied Photophysics) was used to study the 
kinetics of oxygen dissociation and NO caused oxidation of oxyHb. Both free Hb and Hb-
RBCMs were saturated with oxygen before measurement by purging air into the solution or 
suspension for 0.5 h. NO stock solution with 2 mM concentration was received from 
Shoenfisch’s group and stored in tightly sealed tube in 4 °C, and was used within 2 days. 
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Dilutions of NO solution were prepared using deoxygenated PBS by purging PBS with Argon 
for 0.5 h.  
For oxygen dissociation study, by quickly mixing 0.5 µM free Hb (thus 2 µM heme) or 
Hb-RBCMs (R=0.9) with the same Hb concentration, with 0.9 mM sodium dithionite, the 
absorbance change at 436 nm was recorded to monitor the decrease of oxyHb. Since light 
scattering from particles also contributed to absorbance, the absorbance change was normalized 
to plot the change versus time. NO caused oxidation of oxyHb was studied by measuring the 
absorbance change at 419 nm after quickly mixing 0.5 µM free Hb or Hb-RBCMs with 14 µM 
NO solution. Excess NO was used to ensure the kinetics followed pseudo-first-order. The 
absorbance change was normalized to plot the change versus time.  
3.3.12 Microfluidics 
Refer to 2.4.7 for device fabrication. Dilute solutions of Hb-particles (1–5 μg∕mL in PBS 
with 0.1% PVOH) were pumped through the channel and observed with a fluorescence 
microscope (Olympus IX81). Videos were taken with a CCD camera (Hamamatsu). Particle 
stretching was analyzed with ImageJ (NIH) software. 
3.3.13 Rheological measurement 
A rotational rheometer (ARES-G2, TA instrument) was used for the measurement of 
viscosity at different shear rates. To obtain fluid packed with more particles, the particle 
suspension was spun down and decanted to adjust the volume fraction of the pellet to the overall 
fluid volume. Briefly, for a 10 mL suspension containing 10 mg of particles (only considering 
the weight of the polymer), the volume of the pellet after centrifugation at 8,000 g for 8 min was 
around 100 µL. The volume of PBS buffer on top of the pellet could be decanted to be 150 µL, 
resulting in a packed particle volume fraction of 40%. The final hemoglobin concentration  
 75 
[Hb] =
10	   ×  
250	  
= 40 ∙  		
mg
mL
= 4 		g/dL				( : loading	Ratio) 
 
Two hundred microliters of blood or particle suspension ([Hb]=5.2 g/dL; R=1.3) were 
loaded onto the rheometer stage. The stainless steel plate had a diameter of 40 mm with a cone 
angle of 0.0399 rad. The samples were sheared from 0.1 to 1,000 1/s within 3 min while the 
temperature was maintained at 25 °C. The mouse blood samples were collected from Balb/c 
mice into heparinized eppendorf tubes kept at 4 °C and tested within 24 h.  
3.3.14 Cytotoxicity study 
Human umbilical vein endothelial cell (HUVEC) or HeLa cells were seeded in 200 μL of 
media (HuMEC containing HuMEC supplement and bovine pituitary extract or MEM containing 
Earle’s salts and both supplemented with 10% fetal bovine serum) at a density of 5,000 cells per 
cm2 into a 96-well microtiter plate. Cells were allowed to adhere for 24 h and subsequently 
incubated with RBCM particles at concentrations ranging from 200 μg∕mL to 1.56 μg∕mL for 72 
h at 37 °C in a humidified 5% CO2 atmosphere. After the incubation period, all 
medium/particles were aspirated off cells. The ATP-luciferase assay requires 100 μL fresh 
medium, which was added back to cells, followed by the addition of 100 μL CellTiter-Glo® 
Luminescent Cell Viability Assay reagent (Promega). Plates were placed on a microplate shaker 
for 2 min, then incubated at room temperature for 10 min to stabilize luminescent signal. The 
luminescent signal was recorded on a SpectraMax M5 plate reader (Molecular Dynamics). The 
MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium)] viability assay utilizes 20 μL of CellTiter 96® AQueous One Solution Reagent 
(Promega) into each well of the 96-well assay plate containing the samples in 100 μL of culture 
medium. Plates were incubated at 37 °C for 1–4 h in a humidified, 5% CO2 atmosphere. The 
absorbance at 490 nm was recorded using a SpectraMax M5 plate reader (Molecular Dynamics). 
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The viability of the cells exposed to the RBCM particles was expressed as a percentage of the 
viability of cells grown in the absence of particles. 
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3.4 Figures 
  
Figure 3.1  Fluorescent micrograph of polymerized particles (fabricated from 88.85 wt% HP3A, 
10 wt% CEA, 0.05 wt% PEG4kDA, 1 wt% photo-initiator, 0.1 wt% PolyFluor 570) in the mold 
(A), and fully hydrated particles free of the mold, suspended in PBS (B). Scale bars=20 µm. 
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Figure 3.2  Scheme for the conjugation chemistry between carboxyls of particles and lysines of 
Hb. 
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Figure 3.3  Conjugation of Hb to RBCM particles.  Dyeless particles reacted with Fluorescein-
tagged Hb (A) and Rhodamine tagged Hb (B).  Fluorescein-labeled RBCM particles reacted with 
Rhodamine-tagged Hb were observed in the (D) Fluorescein, (E) Rhodamine channels of 
fluorescence; (F) overlay of D and E. Scale bars=20 µm. (G) FTIR spectra of blank particles, Hb, 
and Hb-RBCM conjugate. The arrow pointing to 1579 cm-1 denotes the peak of carboxylate in 
the particles; the two arrows pointing to 1550 and 1660 cm-1 denote the amide groups in Hb. 
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Figure 3.4  Dyeless particles (A) conjugated with AF488-BSA (B). The green background in B 
is actually stream of particles flowing during the capturing of the image. For determination of 
loading ratio, dyeless BSA was conjugated to particles with a feeding ratio of 1 mg particle : 2 
mg BSA, and we found that 0.4 mg BSA (using Coomassie’s assay and plate reader to determine 
the difference before and after reaction) became conjugated after reaction for 12h. 
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Figure 3.5  A 3D reconstruction view of fluorescein-Hb-conjugated particles observed using xyz 
scan mode of the confocal laser scanning microscope, with the inset showing orthogonal cross-
section views of a representative particle (indicated by the white arrow).  The fluorescent protein 
seems to be homogenously distributed throughout the hydrogel particle.  
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Figure 3.6  (A) Loading ratio R and the encapsulation efficiency of Hb into the RBCM particles 
with respect to different starting concentration of Hb for the conjugation while the particle 
concentration was maintained at 1mg/mL (n = 3). (B) RBCM particle size with respect to 
different loadings of Hb; the size of the particles were measured by analyzing fluorescent 
micrographs of the particles (n = 50) which had polymerized Rhodamine dye inside. 
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Figure 3.7  (A) Far-UV circular dichroism spectra of pure Hb, Hb physically mixed with 
particles (Hb+particles), and Hb conjugated to particles (Hb-c-particles). For Hb-c-particles, the 
sample was half diluted as Hb-c-particles Diluted to confirm the isodichroic point as denoted by 
the arrow. The spectra were all measured in 10 mM K2HPO4 buffer with a path length of 1 mm. 
(B) Soret CD of the first three samples with Hb concentration of 1 mg/mL in 10 mM K2HPO4 
buffer. (C) UV-vis spectra of Hb-particles with the hemes of Hb at different binding states. 
Particle concentration in the sample was 0.05 mg/mL with Hb concentration of 0.14 mg/mL. The 
as prepared Hb-particles showed a Soret peak at 405 nm, indicating mostly metHb in the 
particles. When sodium dithionite was added to the particle suspension, metHb was reduced back 
to deoxyHb, characterized by the Soret peak at 430 nm. Carbon monoxide purged into the 
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suspension converted deoxyHb into CO-Hb as the Soret peak moved to 419 nm. When exposed 
to light and air, the Soret peak of the suspension moved to 412 nm, indicating formation of 
oxyHb. (D) MetHb level in polymer-Hb conjugate over time. The polymer was based on a 
similar formulation as for the particles but without crosslinker. Overall Hb concentration in the 
conjugate solution was 5 mg/mL. 
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Figure 3.8  Time courses of (A) oxygen dissociation and (B) NO oxidation of oxyHb. Hb 
concentration was 0.5 µM after mixing in all the studies with 14 µM NO solution to ensure 
pseudo-first-order reaction by large excess of NO. All the measurement carried out at 23 °C. 
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Figure 3.9  (A) Image sequence (top to bottom) showing how a single particle (R = 2.8) passed 
through a constricted pore (from left to right). The time lapse between the frames was 31 ms. (B) 
Clogged pore entrance by Hb-RBCM particles with R = 5.1. (C) and (D) Rheological results 
showing viscosity and shear stress versus shear rate for blood of two mice and Hb-RBCM 
suspension ([Hb]= 5.2 g/dL) that had been subjected to a rheometer. The shear rate ranged from 
0.1 to 1,000 1/s, covering the possible shear rates in blood flow. (E) Microscopic image showing 
intact Hb-RBCM particles after being sheared at a constant rate of 1,000 1/s for 10 min. Scale 
bars = 20 µm. 
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Figure 3.10  Cytotoxicity of the RBCM particles tested on (A) HUVEC and (B) HeLa cells after 
72 h. RBCM particles with 10, 20, and 50 wt% CEA, but unloaded with Hb were studied to 
assess the biocompatibility of CEA. Hb conjugated particles (10 wt% CEA; R=2.8) with metHb 
reduced were tested with their un-reduced counterparts. Fluorescent micrographs of (C) 20 wt% 
and (D) 50wt% CEA particles. The size of the particles were 6.5 and 7.5 µm, and the zeta-
potential were -23.5 and -29.9 mV respectively.  
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Figure 3.11 Standard curve of Hb measured by UV-vis spectroscopy, and fitted by linear 
regression. At 540 nm, the molar absorbance of oxyHb, deoxyHb, and metHb are the same.  
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CHAPTER 4: MODULATING BIODISTRIBUTION AND EXTENDING CIRCULATION OF 
HB-LOADED RBC MIMICS 
 
4.1 Introduction 
Most mammalian cells bear a negative surface charge as measured by electrophoresis. 
This means that, despite presence of both cationic and anionic groups from carbohydrates and 
proteins on the cell surface, overall there are more anionic groups than the cationic ones. RBCs, 
are generally more negatively charged on the surface than other cells resulting from carboxyl 
groups of sialic acid distributed on their membrane.1  The negative surface charge makes RBCs 
stable in plasma, preventing aggregation.2 The amount of sialic acid is a major factor in 
distinguishing young and senescent RBCs. It has been suggested that senescent RBCs are less 
negatively charged, due to reduction in sialic acid, than normal ones, hence being recognized and 
destructed by macrophages.3 Removal of sialic acid on healthy RBCs by neuraminidase could 
also lead to recognition of the RBCs by the MPS.4,5 
Increasing the negative charge on RBC surface, however, would also lead to removal of 
the RBCs. There are four major types of lipids making up the RBC membrane, and phosphatidyl 
serine (PS) is a negatively charged lipid that is exclusively distributed within the inner leaflet of 
RBC membrane. Exposure of PS, under certain circumstances like sickle cells,6 leads to more 
negative charge on RBC surface, and removal of the cells by macrophages. Therefore, it seems 
that there is a window for ζ-potential of RBCs to ensure sufficient circulation time of the cells; 
too high or too low of a negative charge would lead to recognition and clearance of RBCs by the 
MPS. Although it has not been fully elucidated how the surface charge of RBCs influence their 
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function and clearance in details, it is clear that the surface properties follow design rules, which 
may have implications for design of synthetic particles. 
For micro- or nanoparticles, surface charge, along with other physical parameters 
including size, shape and modulus, affects the circulation in blood. Macrophages in the MPS are 
highly capable of recognizing and phagocytizing alien particles or cells depending on all these 
parameters. For surface charge alone, it is generally accepted that macrophages tend to recognize 
charged particles easier than neutral ones, and this tendency intensifies as the absolute value of ζ-
potential of particles increases.7 Once administered to blood, cationic particles are known to 
form aggregates in the presence of the negatively charge serum proteins.8 The aggregates can be 
too large to flow through capillaries in the lung. Positively charge particles may also cause 
several complications such as hemolysis and platelet aggregation.9,10 
A general method to avoid scavenging by the macrophages of the MPS, and to extend 
circulation time of particles, is to camouflage the surface of particles with neutral, hydrophilic 
polymers like poly(ethylene glycol) (PEG). PEGylation, generally indicating attachment of PEG 
to particle surface, can make the resultant particles stealthy to macrophages by repelling plasma 
protein from coating the particle surface.11,12 The molecular weight and conformation of PEG are 
important parameters governing the clearance of PEGylated particles. In our lab, 200×200 nm 
PRINT nanoparticles had been PEGylated to obtain a “brush conformation”, i.e. densely packed 
PEG layer, resulting in much longer half-life than the unPEGylated particles, or particles less 
densely packed with PEG that exhibited “mushroom conformation”.13 Another polymer of 
interest for this purpose is zwitterionic polymer that contains both cationic and anionic charges in 
the same molecule. For liposomes, PEG may destabilize the lipid membrane because of the 
amphiphilic property of PEG, while zwitterionic polymers could make liposomes stable as 
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studied by Jiang’s lab.14 They tested liposomes coated with zwitterionic polymers, and found 
extended circulation time for the resultant liposomes.15 
For Hb-loaded RBC mimics, the particle surface became attached with Hb, a protein that 
is supposed to be encapsulated within cells. Exposure of Hb on particle surface may impair the in 
vivo circulation either due to particle aggregation or easier recognition by the MPS.  
Methods are needed to avoid exposure of Hb on particle surface. While different 
PEGylation methods have been employed to functionalize a wide variety of particles, one thing 
in common is that the intent is for PEG molecules to provide dense protective conformation on 
the surface of particles. For Hb loaded PRINT RBC mimics, however, it would be impossible to 
obtain a dense layer of PEG on the particle surface because there is no solid, continuous surface 
that is generally found in other nanoparticle systems. PEGylating Hb on such a particle surface 
would probably result in a low density of PEG and loss of extended conformation. Moreover, 
there are both carboxyl and amine groups on Hb surface; PEGylation through linkage to lysines 
would make surface-bound Hb more negatively charged, driving the charge of particle surface 
further away from neutral. While it is possible to PEGylate both carboxyl and amine groups of 
Hb attached, it is very complicated and may also cause adverse effect to the structure and 
function of Hb.  
Herein, a strategy to solve the above-mentioned problem is proposed and tested. The idea 
is to load Hb into the interior of PRINT particles but not on the surface. To realize this, a particle 
with conjugation handles only in the interior is needed. The surface, rather than attached with 
protein, should remain neutral and hydrophilic. Because of the chemical homogeneity of PRINT 
particles, post-modification of as-prepared particles is necessary to construct such a particle 
structure. After obtaining PRINT particles with a uniform distribution of functional groups, 
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PEGylation will be carried out to quench the functional groups on particle surface only while 
preserving them inside. However, for PRINT RBC mimics fabricated in previous chapters, the 
highly swollen nature in aqueous solution made them permeable even to large PEG molecules up 
to 30 k Da, making functional groups in the interior also available and reactive toward the 
PEGylation strategy. While these soft RBC mimics could deswell in a non-polar solvent to a 
dense state that may impede diffusion of PEG molecules, the particles were severely aggregated 
due to insufficient surface charge for stabilization. In an alternative approach here, an acid-labile 
crosslinker was used in the particle formulation to yield a high crosslink density, and PEGylation 
was conducted on the surface only, followed by swelling of the particles through degradation of 
the crosslinker. Through the new strategy, swollen particles with neutral surface and charged 
groups in the interior can be obtained. Conjugation of Hb into the particles could generate new 
RBC mimics with Hb loaded predominantly into the interior of the particles. The scheme in 
Figure 4.12 illustrates the procedure for constructing the new RBC mimics. Primary-amine 
containing particles were fabricated as the starting point rather than CEA containing ones 
because primary amines can be simply converted to carboxyls when needed and are much easier 
to quench than carboxyls. 
In addition, we tested the new particles both in vitro and in vivo to demonstrate the effect 
of surface properties of the RBC mimics on their interaction with biological barriers. 
4.2 Results and Discussions 
4.2.1 Synthesis of Acid-labile Crosslinker 
An acetal-based diacrylate (ADA; Figure 4.13A) was synthesized and characterized by 
NMR (Figure 4.13B). ADA, as a hydrophobic crosslinker, is derivatized from HEA, which has 
been proven to be great material in fabricating highly deformable gels in our previous study.16 
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Acetals, with a general structure of R2C(OR')2, are stable under neutral and alkaline conditions 
but readily undergo hydrolysis in aqueous acidic solutions, hence being widely used in drug 
delivery for controlled release.17–20 The R group can be selected to control the degradation rate, 
which can be estimated by the stability of the liberated oxonium ion as degradation 
intermediate.21 For example, methyl as R would make the oxonium ion more stable than 
hydrogen, leading to faster degradation rate. Here we used two methyl groups as R because of 
ease for synthesis and an optimal degradation rate ADA demonstrated. After degradation, a 
single ADA molecule would generate two HEA molecules with one acetone molecule, making 
purification of degraded particle easy by centrifugation. 
The reaction between HEA and 2-methoxylpropene in the presence of organic acid PPTS 
to synthesize ADA is not new. Similar reactions had been done by Frechet17 and Willson22 
before where a high temperature was required. However, we found that at high temperature, 
there was a trans-esterification reaction between HEA molecules, generating ethylene diacrylate, 
a non-degradable crosslinker. Even very low amount of this short-chain non-degradable 
diacrylate as byproduct in ADA could make PRINT particles unable to swell to desired size even 
after complete degradation of ADA. And ethylene diacrylate was very difficult to remove from 
ADA since they had almost the same mobility on TLC plate for many elution combinations 
tested. Therefore, to avoid the complication of ethylene diacrylate generation at high reaction 
temperature, we carried out the ADA synthesis in an ice bath, and found that the reaction could 
still continue, with a 1:1 molar ratio of the two products generated. ADA could easily be 
separated from the mono-protected HEA by common column chromatography. 
 97 
4.2.2 ADA-crosslinked PRINT Particles 
Using the 2 µm PRINT mold, tightly crosslinked particles containing either AEM or 
CEA with the formulations in Table 4.1 could be fabricated. For AEM containing particles, 
HP3A was used to increase the solubility of AEM because the major component ADA (50 wt%) 
was not polar enough. HP3A was also used in the formulation for CEA containing particles for 
better comparison with AEM particles. Non-degradable crosslinker PEG4kDA, a long chain 
PEG diacrylate used to crosslink previous blank RBC mimics, was also lightly used in both 
scenarios to ensure swelling but not complete dissolution of particles after acetal degradation. 
The size of the as prepared particles with CEA or AEM was 2.5 µm (Figure 4.14A) and 
2.3 µm (Figure 4.15A) respectively when suspended in PBS, with zeta-potential of -28 mV and 
22 mV measured in 0.1X PBS. When suspended in pH=3 buffer, the CEA containing particles 
could swell to a maximal size of 5.5 µm after 3 h (Figure 4.14B), while AEM containing 
particles swelled to a maximal size of 5.0 µm after 2 h (Figure 4.15B). It took longer time for 
ADA to completely degrade in CEA containing particles because the carboxyl groups of CEA 
would be protonated at pH = 3 (pKa of CEA around 4), making the particles more hydrophobic 
for diffusion of proton and acetone. 
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Table 4.1  Compositions used to fabricate tightly crosslinked particles. Both AEM and CEA 
containing particles were fabricated. 
Component Weight percent (wt%) Function 
Cationic Anionic 
HP3A 28-28.9 27-27.9 Improving solubility of AEM 
AEM 18 0 Amine containing monomer 
CEA 0 20 Carboxyl containing monomer 
PEG4kDA 2 1 Non-degradable crosslinker 
DEAP 1 1 Photoinitiator 
ADA 50 50 Degradable crosslinker 
fluorescent dye 0.1-1 0.1-1 Imaging 
 
4.2.3 PEGylation of ADA-crosslinked Anionic Particles 
Our initial attempt was to start with CEA containing particles with a high crosslinking 
density, to obtain a neutral surface but with an anionic interior for loading with Hb. By adding 
EDC/NHS or EDC/sulfo-NHS to activate the carboxyl groups in particles, methoxyl-PEG-amine 
(mPEG-amine) was added with the intention to react with carboxyl groups on particle surface 
only. We found that mPEG-amine with molecular weight (MW) ranging from 5 k to 30 k Da 
could all screen the surface charge of the particles, as zeta-potential of the PEGylated particles 
could decrease to neutral, with high MW mPEG-amine being more efficient. However, after 
treatment of the PEGylated CEA particles in pH = 3 buffer even for extended hours, the expected 
swelling did not occur as the particles just slightly increased their size (Figure 4.14C, D). 
The insufficient swelling of PEGylated CEA particles was found to be caused by side 
reactions of the activated carboxyls. It has been known that carboxyl activated by carbodiimide 
can undergo the [O→N]-Acyl migration reaction to generate O-acylisoureas.23 This side reaction 
could happen within the particle interior, resulting in a decrease in the available amount of 
carboxyls because EDC or other carbodiimides are small molecules and could penetrate the 
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particle even highly crosslinked by ADA. The generated O-acylisoureas are positively charged, 
and could interact with negatively charged carboxyls remained to form physical crosslinks. 
To avoid the side reactions of using carbodiimide, other carboxyl-activators including the 
uranium reagent TSTU and HATU, and triazine reagent DMT-MM,23,24 had also been tested, yet 
the same problem remained. What probably happened was that these small-molecule activators 
infiltrated into the interior of particles to activate the carboxyls, which had no amine to react with 
because of the size exclusion for mPEG-amine, leading to crosslinking with hydroxyls of HP3A. 
Even when HP3A was replaced by another hydroxyl-free monomer, methoxyl-PEG (MW = 480 
Da) acrylate, insufficient swelling still occurred, possibly because of trace amount of hydroxyl 
impurities in the new monomer, or hydroxyls generated by partially degraded ADA.  
Overall, even though highly crosslinking of the CEA containing particles by ADA could 
ensure confined PEGylation only on the particle surface, carboxyls within the particle interior 
could readily be activated toward undesirable side reactions that caused extra crosslinking. The 
final size and deformability of the particles eve after ADA degradation would be greatly 
affected. To circumvent the problem, AEM particles crosslinked by ADA were used as 
alternative, since the primary amines could be easily converted to carboxyl. 
4.2.4 PEGylation of ADA-crosslinked Cationic Particles 
The AEM containing particles with the formulation in Table 4.1, denoted as particle A as 
following the nomenclature in Figure 4.12, could degrade quickly in pH = 3 buffer, while 
remained minimally swollen in PBS (pH = 7.4) for an extended time (Figure 4.15C). This 
pronounced difference in degradation rate in different pHs made ADA crosslinked particles 
attractive for our purpose, as rapid degradation in pH = 3 could shorten the work-up time, yet 
stability in PBS  allowed storage before further reactions were carried out. 
 100 
Amine reactive PEGs such as mPEG-NHS are extensively used to PEGylate both 
proteins25 and particles13. However, in our study here, we found that all the commercially 
available mPEG-NHS reagents needed to be purified for the quenching of surface amines, 
otherwise a similar problem of insufficient swelling of particles after acid treatment always 
occurred without exception (Figure 4.16A). The reason was probably due to a β-alanine 
impurity in the commercial products. Generally, mPEG-NHS is synthesized by activation of the 
carboxyl of mPEG-COOH using combination of DCC and NHS, or similar activators in organic 
solvents. However, excess DCC and NHS can form a byproduct  β-alanine, which is a small 
molecule having NHS groups at both ends.26 Even though the impurity quantity may be low, it 
could act as a short-chain crosslinker within the interior of particle A. 
Since the β-alanine impurity is a small molecule, it has distinct solubility from mPEG-
NHS in IPA, based on which we purified mPEG-NHS with different MWs. AEM particles 
PEGylated with the purified reagents could swell to the desired size after acid treatment (Figure 
4.16B). 
Table 4.2  ζ-potential of particle B and C when mPEG-NHS with MW of 2k, 5k and 30 k Da 
were used for the PEGylation for 4h. 
MW of mPEG-NHS (Da) 2k 5k 30k 
Zeta potential (mV) 
B 2.23 2.12 0.85 
C 2.54 4.86 5.27 
 
The efficiency of mPEG-NHS with MW of 2k, 5k and 30k Da on quenching the amines 
on particle surface was compared by measuring the ζ-potential of particles after PEGylation 
under similar conditions. At the same molar stoichiometry of mPEG-NHS used for the same 
weighted particles, higher MW PEG was more efficient in screening the surface charge as the 
corresponding ζ-potential of particle B (PEGylated version of particle A) became closer to 0 mV 
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(Table 4.2). This is reasonable because longer PEG chains could extend out to shield the charge 
better. However, after pH = 3 degradation to swell the particles, ζ-potential of particle C 
(degraded derivative of particle B) showed the opposite trend against MW. Therefore, longer 
PEG could shield the charge more efficiently in particle B, yet was less efficient in actually 
quenching the amines because the larger size limited efficient grafting of PEG molecules to 
surface of B, making more remaining amines exposed to surface of C. As a trade-off between an 
efficient quench of amines on the particle surface and limited diffusion into interior of particles, 
we chose an optimal MW of 2k Da for the quench reaction without trying lower MWs.  
We confirmed that PEGylation was limited to the particle surface using a confocal 
microscopic method. A fluorescent probe, fluorescein-PEG2k-NHS was used to react with a 
dyeless model particle that were fabricated with the same composition as particle A but in 
PRINT mold with larger cavities (7×7×3 µm) for better visualization. After PEGylation under 
the same condition as particle A was treated with mPEG2k-NHS, the model particles were 
thoroughly washed and observed under a confocal microscope. As can be seen in Figure 4.16C, 
a ring-like fluorescence pattern was present, indicating distribution of fluorescein-PEG2k-NHS 
only on the particle surface. In a control, when fluorescein-NHS (MW=473 Da) was used to 
quench the particles under the same condition, a disc-like fluorescence pattern was shown 
instead (Figure 4.16D). With identical compositions, particle A should have similar pore size as 
the model particle, therefore similar diffusion barrier for mPEG2k-NHS. We could therefore infer 
that PEGylation on particle A was limited to the surface only. 
4.2.5 Quantifying Amine Contents in Particles 
 The fluorescence-based microscopic method described above implies that mPEG2k-NHS 
reacted with amines of particle A in a gradual way from surface toward the interior, and the 
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reaction was possibly limited to a certain depth. However, it would be inaccurate to assess the 
diffusion depth by measuring the width of the fluorescence band. Instead, we used a quantitative 
fluorescent assay to measure how much primary amine is left in the particles. In this method, 
fluorescein-PEG2k-NHS was added to particles of interest to label the amines by fluorescein. 
PEG was used to ensure stability of some particles that otherwise aggregated when fluorescein-
NHS was used. From the 1 : 1 stoichiometry, the amine content can be calculated from the 
quantity of dye, which can be fitted using the standard curve of fluorescein-PEG2k-NHS 
regarding excited fluorescence.   
Direct degradation of particle A generated particle F. Using the fluorescent assay 
describe above to, we found that from 1 mg A, there were 0.82 µmol NH2 in generated particle 
F. When particle F was PEGylated even using the largest MW PEG-NHS available, mPEG30k-
NHS, the remaining amount of –NH2 was quantified to be less than 10% of the original total. In 
contrast, in particle C, there were 72.1% NH2 as of F from the same starting amount of particle 
A. 
The results of amine quantification confirmed it was necessary to develop the confined 
PEGylation on tightly crosslinked particles so that most interior amines could be preserved, 
while direct PEGylation of swollen particles led to excessive consumption of amines. It is 
noteworthy that, swollen particles like F would further swell after PEGylation because the 
incorporated PEG molecules could absorb water and repel each other, even though the charged 
groups were diminished. 
4.2.6 Succinylation of AEM-particles 
Succinic anhydride (SA) was used to convert the amines of AEM into carboxyls. The 
reaction was carried out in 10X PBS to retain a stable pH. When 1X PBS was used, the pH 
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could, due to hydrolysis of largely excess SA, decrease to around 3, at which amines would be so 
protonated that succinylation could not continue.  
Succinylation of particle C into particle D, reversed the ζ-potential to slightly negative as 
-6 mV (Figure 4.18A), which could be considered as near-neutral generally. In contrast, particle 
G, succinylated derivative of particle F, reversed the charge from 28 mV to -32 mV (Figure 
4.18B). 
The succinylation reaction was very efficient in converting amines to carboxyls, as no 
remaining NH2 was detectable using the fluorescent assay described in 4.2.5. 
4.2.7 Conjugation of Hb 
Conjugation of bovine Hb into particle D or particle G followed previous method 
explicitly described in 3.2.4. For particle D, because of absence of carboxyl on the surface, 
conjugation could be carried out in concentrated suspension without inter-particle crosslinking or 
aggregation. However for particle G, as there were many carboxyl groups on particle surface 
implied by a ζ-potential of -32 mV, which was even more negative than blank particles made in 
3.2.1 (ζ-potential = -18 mV), the conjugation had to be conducted with low concentration; 
otherwise, severe aggregates and sedimentation would form during the reaction (Figure 4.19A). 
We maintained low concentration during conjugation for both particle types for comparison. By 
normalizing the numbers of particles to fixed weight of particle A, we could calculate the loading 
of Hb into particles generated from 0.2 mg (ca. 10 million) particle A as: 0.21 mg Hb in E, and 
0.19 mg Hb in H.  
A turbidity assay was applied to both particles E and H, when the two suspensions with 
optical density (OD) of 1 were quickly mixed with fetal bovine serum (Figure 4.19B). The OD 
at 720 nm, at which absorbance of Hb was negligible, decreased gradually because of particle 
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sedimentation due to their large size. The rate of OD change for particle E was slower than that 
of particle H, indicating less inter-particle aggregation.  
4.2.8 Particle Interaction with Macrophage  
To assess the effect of surface properties of these RBC-sized particles on their in vivo 
circulation and biodistribution, we first studied their interaction with macrophages in vitro. We 
dosed all the different types of particles from A to H to the Raw264.7 (mouse leukaemic 
monocyte macrophage) cell line, with about 400 particles/cell to a total of 105  cells. After 
incubation for 4 and 24 h, percent of macrophages that were associated with particles were 
measured by flow cytometry and presented in Figure 4.20A. Particles with quenched surfaces 
(B, C, D, E) all showed much lower association than the starting particle A and unquenched 
particles (F, G, H), indicating reduced interaction between quenched particles and macrophages. 
Hb loaded particles H, counterpart of E, were highly associated with the macrophages probably 
due to presence of Hb on particle surface. Our results agreed with previous knowledge that 
neutral particles have less interaction with macrophages than charged particles.7 While particle A 
and F, amine containing particles, displayed cytotoxicity to the cells (Figure 4.20B), PEGylated 
particle C with interior amines showed minimal cytotoxicity similarly to other particles, 
confirming effective surface quenching. 
4.2.9 in vivo Studies 
To compare the in vivo performance of all the RBC-sized particles (C to H), an intravital 
microscopic imaging method, was used to observe the particles when intravenously injected into 
balb/c mice. Intravital microscopy (IVM) has been used to assay the accumulation of targeted 
particles in tumors27 and tissues;28 it has also been proven to be a reliable method in evaluating 
the circulation of both micro- and nanoparticles in our previous studies.13,16,29 DyLight 680 was 
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copolymerized into all the particle sets; we observed the peripheral vasculature through the skin 
of an anesthetized mouse’s ear to track the near-IR fluorescence of injected particles every 5 s 
for 2 h (Figure 4.21A). Elimination curves could be generated by plotting the change in 
fluorescent signal from the particles over time normalizing each scan to the maximum intensity 
slice. 
As anticipated, particles with quenched surface showed extended circulation than their 
unquenched controls. Particle D demonstrated the longest circulation (Figure 4.21B) of all the 
particles tested. With a small bump in the clearance curve, indicating release of some of the 
physically entrapped particles back to blood similar to what we had observed before for blank 
RBC mimic (Figure 2.7),30 the clearance curve of particle D cannot  be fitted for a conventional 
pharmacokinetic model, at least within the 2 h time frame. After 2h, particle D was highly 
concentrated in the spleen, a characteristic of highly deformable particles of this size.30 
Negatively charged particle G (ζ-potential = -32 mV) had a clearance curve that could be well 
fitted using the two-compartment pharmacokinetic model (2.4.10), which has often been 
appropriate to describe the behavior of particles in circulation.31 The calculated elimination half-
life  (t1/2β) of 0.5 h is much shorter than that of blank RBC mimics (ζ-potential = -18 mV; t1/2β = 
85 h30), yet the biodistribution of G was very similar to both D and previous blank RBC mimics, 
indicating  quicker clearance of G by the MPS system since it is known that more charged 
particles tend to attract macrophages more.32,33 
Loaded with hemoglobin, particle E also showed similar biodistribution pattern as D and 
G. The fitted elimination half-life of 1.2 h, was way more better than particle H, which was 
rapidly removed from circulation as only insignificant fluorescence observed all through the 
imaging process (Figure 4.21A shows the fluorescence after 100 secs post injection). 
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Biodistribution after 2 h showed drastically high accumulation of H in the lung (Figure 4.23). 
Since the lung is the first downstream tissue with microvasculature post injection, we could 
speculate that most of the dose sequestered immediately after injection of H because of 
aggregates formed as evidenced by tissue staining result (Figure 4.22). 
Table 4.3  Two-compartmental analysis of RBC-sized particles from intravital microscopy 
experiments. The clearance curve of Particle D cannot be fitted using 2-compartment model. 
Particle Distribution half-life, 
min 
Elimination half-life, 
min 
AUC, 
fluorescence×min 
C 1.3 20.5 10.7 
E 6.2 73.9 25.3 
G 5.4 29.1 29.8 
D NA NA 62.3 
Compared to neutral or negatively charged particles, positively charged ones tend to 
interact more with plasma proteins, most of which are negatively charged,7 leading to fast 
removal. Indeed, positively charged particle F was instantly removed from circulation (Figure 
4.21A) similarly to H, and most of the particles ended up in the lung (Figure 4.23). Adsorption 
of proteins onto F probably led to aggregation and hence sequestration in the lung. Interestingly 
for particle C, we observed strong fluorescence from the particles in the early time points post 
injection (Figure 4.21A). However, compared to particle D, the clearance rate of C was much 
faster (t1/2 = 20.5 min), with both spleen and liver as the major disposition tissues. Because of the 
deformability and neutral surface of C, the bulk of the dose were able to traverse the lung post 
injection in contrast to F. However, the high porosity in these swollen microgels might have 
allowed plasma proteins to infiltrate into the particles gradually, leading to easier recognition of 
C by the MPS system most prevalent in the spleen and liver. 
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4.2.10 Conclusions and Future Work 
To further mimic true RBCs in regard to confined distribution of Hb, we designed a new 
particle D with neutral surface and charged groups inside, and loaded Hb into the particle in a 
confined fashion without or with only minimal exposure of the protein to particle surface. 
Through the IVM and tissue imaging studies, we found that surface properties indeed dictated 
both circulation and biodistribution when other factors were similar. All the particles with 
quenched surface, i.e. PEGylated surface, showed longer circulation than the corresponding 
counterparts with charged surface.  
For the proposed PEGylation method here, the selection of an optimal MW is critical. In 
the tight state before degradation, the particle surface could be easily neutralized due to charge 
screening by PEG. However, after degradation of ADA and swelling of particles, physically 
screened but not chemically quenched charges could come into effect. Moreover, some charges 
close to the surface but originally buried inside may become exposed after degradation. This is 
why from particle B to C, increase of ζ-potential was always observed for the different PEG-
NHS used. Therefore, the PEG reagent used should be able to diffuse toward the interior to 
certain extent in order to quench charges on and close to the surface. To this end, the smaller 
MW of PEG-NHS, the better. However, PEG-NHS with too small MW may permeate into the 
particles so easily and fast that most of the interior charges would also be quenched. We opted to 
use PEG-NHS with MW of 2 k Da because of its smaller size compared to the more generally 
used PEG of 5 k Da or higher MW, and its limited diffusion rate compared to PEG-NHS with 
MW < 1 k Da (as tested with MW of 510 and 686 Da). If our goal is to merely increase 
circulation time of blank microgels without intention to further functionalize the particles like 
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loading protein, using PEG-NHS to quench charged groups of already-swollen particles may be 
sufficient enough to extend the circulation. 
Compared to conventional PEGylation on nanoparticles, where a dense layer of PEG on 
particle surface was necessary to achieve the “mushroom conformation”, our PEGylation was 
primarily intended to quench the surface charge while maintain particle stability. While it may be 
possible that particle B had a dense layer of PEG covering its surface, the swollen, RBC-sized 
particles from C to E would only have separated PEG chains because of an almost 6 times 
( 
 .   
 .   
 
 
) increase of particle surface area after degradation of ADA.  
While anionic particles could mimic RBCs regarding negative surface charge, there may 
be a strict window for ζ-potential, as decrease from -18 mV (blank RBC-sized particle in 
Chapter 2) to -32 mV (particle G) caused quicker clearance of anionic particles. PEGylation to 
quench the negative charge on particle surface, not only provided stability to the particles, but 
also reduced interaction between the particles and macrophages, leading to the longest 
circulation ever observed in IVM for RBC-sized particles. Therefore, even for highly swollen 
particles that are unable to obtain high density of PEG coverage, PEGylation to neutralize 
surface charge may still extend circulation as it does to solid nanoparticles. 
Using the IVM method here, we could definitely compare circulation half-lives of the 
different particles and confirm the advantage of surface-quenched particles. The calculated 
clearance half-life from the 2 h intravital curve was 1.2 h for particle E, similar to the half-life of 
cell-free Hb. To accurately evaluate the half-life of particle E, blood draw method will be needed 
and a longer circulation time may possibly be calculated. Some long circulating particles may 
still be within the distribution phase during the 2 h scan by IVM. Blood draw method spans 
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longer time to ensure coverage over the distribution phase, and can provide more accurate 
estimation of the circulation life. 
Particle E can be potent candidate as oxygen carrier, despite its decreased circulation 
time compared to the blank particles. With such a large size, vasoconstriction may possibly be 
avoided for particle E, because vasoconstriction is inversely proportional to the size of the 
HBOC.34 While early HBOCs based on large sized particles (1-100 µm) were abandoned for 
further test because of blood flow issues, particle E could avoid accumulation in the capillary 
beds in the lung. This feature of particle E is critically important, otherwise particle H would be 
deteriorating cases where an oxygen carrier is needed since particle H would severely block 
capillaries in the lung. 
It has been well known that cationic particles would be cleared from the circulation faster 
than neutral or anionic particles. Our study confirmed this as particle F was rapidly removed by 
the lung. However, by quenching the surface positive charge via PEGylation while retaining the 
cationic charge inside particles, an extended circulation for G was observed, making particle G 
possible to be used for in vivo applications. It is noteworthy that for particle G, spleen and liver 
were the two major organs with similar levels of particle disposition, while for all the other 
RBC-sized particles, either lung or spleen was the only leading organ for particle disposition. 
Since macrophages are most abundant in the spleen and liver, it is hypothesized that some 
plasma proteins could gradually infiltrate into particle G, leading to recognition of particle G by 
the MPS. 
In the future, we can test particle E regarding vasoconstriction. First, we can compare 
cell-free Hb and particle E in an ex vivo model. Solution of cell-free Hb or suspension of particle 
E containing equal concentration of Hb can be perfused through isolated arterioles, 34,35 and 
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possible diameter change of the arterioles can be monitored. With or without flow, cell-free Hb 
would always cause vasoconstriction in this model as Hb molecules could diffuse into the 
endothelial to scavenge NO. In this model, equal amount of Hb either in particles or as free form 
is distributed in the arteriole of interest, so the result can clearly imply how vasoactive the 
particle is compared to fee Hb. Once no vasoconstriction observed for particle E using this 
model, we can continue to study vasoactivity in vivo.  
We can use IVM to study arteriole diameter change in mice dosed with particle E and 
free Hb. Because of different pharmacokinetics of free Hb and particles E, the distribution of Hb 
in particle E into the arteriole of interest may be quite different from that of free Hb even when 
the same dose of Hb administered, so this in vivo study must be accompanied by the ex vivo 
model. Compared to a single time flow in the ex vivo model, there are numerous flows passing 
the arteriole of interest, so the vasoconstriction study in vivo can further reveal vasoactivity of 
particle E under continuous intravascular flow compared to fee Hb. 
Besides Hb, particle D can also be installed with other proteins of interest. The two 
enzymes, superoxide dismutase (SOD) and catalase (CAT) responsible for maintaining low 
metHb in RBCs, can be conjugated to the particle with lower loading prior to Hb conjugation, 
resulting in particles mimicking the enzyme system of RBCs.  
The long circulation time of particle D can possibly be maintained when low amount of 
protein is loaded compared to particle E which was highly charged with Hb. Enzymes that can 
work in plasma without necessity to be delivered into specific cells can be installed into particle 
D at low loading for extended effect. For example, butyrylcholinesterase (BuChE), a natural 
enzyme that can degrade organophosphorus nerve agents, can be loaded into the particles as 
nerve agent scavenger for defense purpose. A pro-drug strategy can also be used to link BuChE 
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to particle D so that the protein can be release over a long time to scavenge nerve agent not only 
in blood but also in muscles and other tissues. 
The scavenging idea can also be applied to cationic particles. Surface neutral, interior 
cationic particle C can bind to nucleic acids through electrostatic forces. After binding, the 
deformability of particle C may be decreased that the particle would be cleared in the spleen. In 
situations where free plasma nucleic acids may cause inflammation,36 the particles can act as 
scavenger to remove the free nucleic acids. As discussed above, the current form of particle C 
might possibly be easily accessible by plasma proteins, leading to clearance in the spleen and 
liver. We can finely tune the pore size in such a surface-neutral, interior-cationic particle so that 
it can selectively bind nucleic acids while excluding proteins that are generally larger. Scaling 
down the pore size may mean higher crosslinking density and less deformability for the particles 
than blank particles studied here. To extend circulation of such particles even after modulating 
the pore size, a smaller particle size than that of RBC may be used so that there is still long 
enough circulation despite less deformability. Because particles for this purpose does not have to 
be in the RBC size range in order to mirror RBC hydrodynamics in intravascular flow to avoid 
vasoconstriction, microgels with smaller size than RBCs may still be a good selection to fulfill 
both specific binding of nucleic acids and extended circulation until becoming too stiff after 
scavenging enough nucleic acids. 
By incorporation of other functionalities into the interior of surface-neutral particles, 
more scavenging functions can be explored, such as removal of lipid,37 and removal of glutamate 
for brain neutraprotection.38 Overall, we believe, by combining PRINT and the proposed strategy 
for selective surface modification, new particles can be created not only as potent oxygen 
carriers, but also as bioscavengers for therapeutic purposes. 
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4.3 Materials and Methods 
4.3.1 Materials 
HP3A was synthesized according to 2.4.2. Pyridinium p-toluenesulfonate (PPTS), 2-
hydroxylethyl acrylate (HEA), 2-methoxylpropene, diethoxyacetophenone (DEAP), 2-
aminoethyl acrylate (AEM), succinic anhydride, bovine hemoglobin, Dulbecco’s phosphate 
buffer saline (PBS) were all received from Sigma-Aldrich. Polyethylene glycol (MW=4,000 
g/mol) diacrylate (PEG4kDA), methacryloxyethylthiocarbamoyl rhodamine B (PolyFluor® 570) 
were from Polysciences, Inc. Sulfo-N-Hydroxysuccinimide (NHS), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC), Fluorescein-NHS, and 2-(N-
morpholino) ethanesulfonic acid (MES) buffer, were all received from Thermo Scientific.  
DyLight 680 was from Piercenet. Methoxy-PEG-NHS with MW of 2k, 5k, 30k were all received 
from Creative PEGworks; fluorescein-PEG2k-NHS was received from Nanocs Inc, and all the 
PEG reagents were purified before use with procedures described later.  All organic solvents and 
acidic buffers were received from Fisher Scientific unless otherwise noted. Perfluropolyether 
molds were received from Liquidia Technologies. 
4.3.2 Synthesis of ADA 
In a typical procedure, 15 g (129 mmol) HEA with 1.5 g (6 mmol) PPTS was dissolved in 
50 mL dichloromethane (DCM) in a 3-neck flask charged with nitrogen purge and a stir bar. The 
flask was kept submerged in an ice bath. Then 5 g (69.4 mmol) 2-methoxylpropene dissolved in 
another 50 mL DCM was gradually added to the flask from an addition funnel during a 0.5 h 
course. The reaction was allowed for 4h. After the reaction, the DCM solution was washed with 
6 wt% NaHCO3 solution 3 times (100 mL each time). To the washed DCM phase, anhydrous 
Na2SO4 was added to dehydrate. The solids were filtered, and then DCM was removed on a 
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rotovap in vacuo to obtain colorless oil (10.5 g).  ADA was separated from the other product in 
the oil using a silica column with elution comprising of 5:1:0.03 of hexane/ethyl 
acetate/triethylamine. Triethylamine was used to avoid degradation of ADA in the column 
because silica gel is slightly acidic. About 3 g of ADA could be obtained. Even though the final 
yield was not high because of the byproduct, we confirmed high purity as no ethylene diacrylate 
was present characterized by HPLC. 
4.3.3 Purification of mPEG-NHS 
For PEG of 5k Da and larger MW, dissolve ~100 mg mPEG-NHS in 50 µL anhydrous 
methanol (Acros), then add 1 mL anhydrous isopropanol (IPA; Acros) to the solution and after 
~5 min, mPEG-NHS would precipitate out. For mPEG-NHS with MW of 2k Da, dissolve ~100 
mg PEG2k-NHS in ~500 µL IPA, and sonicate to dissolve completely. Store the solution at -20 
°C for 3 min and mPEG-NHS would precipitate out. Spin down the PEG solid and repeat the 
corresponding process another 4 times. Collect the final solid and dry in vacuo. Store purified 
solids in a vial top-filled with nitrogen for future use if not used immediately. Purified PEGs 
were used within 2 weeks. 
4.3.4 Fabrication of Particle A 
About 50 µL of the pre-particle solution with formulation in Table 4.1 was applied to a 
PRINT mold using a pipette tip. A  polyethylene terephthalate (PET) sheet was applied on top of 
the mold, and this assembly was passed through a small, non-heated laminator with pressure of 
50 psi to wet the mold completely. After passing through, the assembly was subjected to another 
hot laminator set at 60 oC, 40 psi, and the PET sheet was peeled away at the nip point of the 
laminator, leaving the cavities filled while wicking away excess solution. The filled mold was 
immediately transferred into a nitrogen purged UV oven and cured with UV light (λ = 365 nm, 
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power = 20 mW∕cm2) for 3 min. After curing, the filled mold was placed face down on a thin 
film of 0.1% Plasdone (GAF) in water on top of another PET sheet. This assembly was placed in 
a cooler half-filled with dry ice, allowing the water to freeze and adhere to the particles. After 
freezing, the mold was peeled away from the particles trapped in the ice layer, and the ice was 
allowed to thaw. Particles and water were collected, then washed and concentrated via repeated 
centrifugation at 10,000 rpm (4×3 min each time) in PBS. The concentration of particle 
suspensions was determined by thermogravimetric analysis (TGA) on a Perkin Elmer Pyris 
TGA. Both the suspension and the supernatant after spinning down the particles were subjected 
to TGA at the same volume (20 µL) to obtain the dry weight. The difference in the weight 
divided by the volume was the concentration of that particle suspension.  
4.3.5 Particle characterization 
Particle dimensions were determined by analysis of images taken from a microscope 
mounted camera (Zeiss AxioCam MRm) using a 100× objective (Zeiss Axio Imager D.1M). 
Over 50 fully hydrated particles in PBS were measured for each case. The ζ-potentials for 
particles were measured on a Malvern nano-ZS zetasizer. The particle suspension was spun 
down and resuspended into 0.1X PBS for the measurement at a concentration of around 0.3 
mg/mL. All the experiments were performed at 25 °C. 
4.3.6 Particle A Degradation 
Particle A was dispersed in buffers with different pHs at a concentration of about 0.8 
mg/mL. After certain time points, 100 µL of the suspension was taken out and washed by PBS 
by 3 runs of centrifugation circles. The washed particles in PBS were dropped onto a glass slide, 
covered by a thin glass slip, and then observed under microscope for the size.  
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4.3.7 PEGylation of Particle A 
Typically, 1 mg particle A was suspended in 500 µL PBS. Then 6 mg of mPEG2k-NHS 
(or 15 mg mPEG5k-NHS, or 90 mg mPEG30k-NHS to ensure the same moles of PEG per mg 
particles) in 100 µL PBS was added to the particle suspension and reacted for 4 h on a shaker set 
at 1000 rpm at room temperature. After reaction, the particles were purified by repeated circle of 
centrifugation/washing 3 times. 
4.3.8 Succinylation 
Particle C or F in 1X PBS was spun down and re-suspended in 10X PBS to a 
concentration around 1 mg/mL. To the suspension, 4 mg SA dissolved in 50 µL acetonitrile 
(Acros) was added and reacted for 2h by shaking at RT. After that, the particles were spun down 
and resuspended in 10X PBS, followed by another 4 mg of SA in 50 µL acetonitrile and reacted 
another 1 h. Finally particles were purified by repeated centrifugation/washing circles for 4 
times. 
4.3.9 Hb Conjugation 
Refer to 3.3.8 for the method of conjugation and Hb quantification. For D to E, 2.5 mg 
Hb was added to 1 mg particle D (2 mL PBS), while for G to H, 2 mg Hb was added to 1 mg G 
(in 2 mL PBS) to ensure that no less Hb loaded in E than H because quenching the surface led to 
less carboxyls in E.  
4.3.10 Model Particle PEGylation using Fluorescein-PEG-NHS 
Commercial Fluorescein-PEG-NHS was made by reacting FITC to amine-PEG-COOH 
followed by conversion of COOH to NHS ester. Therefore, there may be remaining FITC in the 
final product. When unpurified product was used to react with dyeless model particles, 
fluorescence was seen all over the particles because FITC could diffuse in to react with interior 
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amines. To purify, dissolve 1 mg fluorescein-PEG2k-NHS in 50 µL PBS and load the solution to 
a small column (Diameter: 0.5 cm, length: 5 cm) packed with Sephadex G-25. Elution with PBS 
could separate fluorescein-PEG-NHS from FITC as PEG would come out first. The collected 
solution of fluorescein-PEG-NHS was added with another 5 mg purified mPEG2k-NHS to 1 mg 
model particles for PEGylation which lasted 4 h by shaking at RT. After reaction, the particles 
were thoroughly washed by PBS 4 times with centrifugation. In a control experiment, the same 
moles of fluorescein-NHS were used to replace fluorescein-PEG-NHS for the reaction. 
4.3.11 Amine Quantification in Particles 
For swollen particles C and F, we used a fluorescent assay to quantify the amine content. 
Both C and F were prepared starting from 1 mg of particle A. To suspensions of C or F in 500 
µL PBS, 10 mg fluorescein-PEG2k-NHS was added and allowed to react for 12 h followed by 
purification. The purified particles were resuspended and diluted to measure fluorescence 
(excited at 492 nm, emission at 518 nm). A standard curve of fluorescein-PEG2k-NHS at 
different dilutions was prepared. Based on the standard curve of fluorescein-PEG2k-NHS, the 
amount conjugated to the particles could be fitted. Based on a 1:1 stoichiometry, the amine 
content was calculated. Herein, fluorescein-PEG2k-NHS was used rather than the small molecule 
fluorescein-NHS because otherwise particle F would stick to reaction vials and could not be spun 
down because of quenching of amines on the surface.  
4.3.12 Normalizing Particle Numbers 
To better compare the performance of all the particles regarding their interaction with 
macrophages, and in vivo circulation, we decided to dose the same numbers of particles rather 
than the same weight because the particles (B to H) had similar shape, size, yet their individual 
weight vary more especially after Hb conjugation.  
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First of all, we could estimate the weight of a single particle A, knowing the dimensions 
of PRINT mold and the pre-mix density, 
m  = ρhπr
  =
1.1g
cm 
× 0.6	μm × 3.14 × 1	μm  = 2.1	pg 
Then, for a single well with 1 × 10 macrophages, the dose would be 400 particles per 
cell, as in weight of 2.1	pg × 400 × 10  = 80	μg for total A dosed.  
For the other particles, to ensure same numbers as 80 µg A, we could start with 8 mg A to 
fabricate different particles and divide the final volume of each particle 100 times to obtain the 
same numbers of particles.  
For animal studies, 10 particles/g mouse weight was dosed for the RBC-sized particles 
from C to H. The dose, in numbers of particles, equaled to the number of 0.4 mg of starting 
particle A for mouse of 20 g body weight.  
4.3.13 Macrophage Interaction Study 
The Raw264.7 cells were cultured with Dulbecco Eagle media which was supplemented 
with 1% penicillin/streptavidin and 10% fetal bovine serum. Cells were grown in standard 
culture conditions (37°C and 5% CO2). The cells were seeded in 24 well plates at a concentration 
of 1×105 per well and left overnight in the incubator. On the next day, the media was replaced 
with fresh media warmed to 37°C just prior to the experiment.  The particle samples (80 µg in 1 
mL water) were incubated with the cells for 4 and 24 h.  Cells grown without any particles were 
used as control. At the set time points, cells were washed three times with 500 µL 1X PBS and 
detached by the addition of 1X trypsin/EDTA (300 µL) to each well.  Following a 5 minute 
incubation (37 °C), 1X DBPS/10% FBS (500 µL) was added to each well and was mixed 
vigorously.  This final solution was then transferred to a polypropylene tube and analyzed using 
flow cytometer. 
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4.3.14 Intravital Microscopy 
Animal studies were carried out in accordance with an animal use protocol approved by 
the University of North Carolina Animal Care and Use Committee.  IVM experiments were 
performed using an IV 100 laser scanning microscope (Olympus) on female balb/c mice of 18 to 
26-g body weight (Jackson Lab). Hair was removed from the ear and a tail vein catheter was 
applied. The mice were anesthetized with isofluorane and placed onto a heated stage (37 °C) in a 
prone position, with an ear immobilized by taping to an aluminum block. Vasculature was 
located by injection with a solution of 5 mg∕mL rhodamine B labeled 70-kDa dextran 
(Invitrogen) in PBS and visualized by excitation with a 568-nm laser. A suspension of particles 
in PBS with 0.05% Tween 80 was then injected and visualized using a 633-nm laser. Imaging 
scans proceeded for 2 h, with an image taken every 5 s. We analyzed the region of interest 
containing vasculature for fluorescent signal in each scan and corrected for variation in laser 
intensity or autofluorescence by background correcting each image with the signal from a region 
of the scan that was free of vasculature. For comparison, we normalized each scan to the 
maximum intensity slice for that scan, providing curves that measured the clearance of particles 
from the peripheral vasculature over time as a percentage of the maximum signal. Harvested 
tissues including liver, lung, spleen, kidneys, heart were weighed, then imaged using an IVIS 
Kinetic fluorescence imaging system (Caliper Life Sciences) with excitation at 675 nm and 
emission measured at 720 nm (NIR dye). Blood was harvested via cardiac puncture and pipetted 
in 100-μL aliquots to black 96-well plates for analysis on the imager. The fluorescent signal for 
each tissue sample was background corrected by subtracting the signal from control tissues. 
Biodistribution profiles for the particles at 2 h postdose were determined by percent of recovered 
fluorescence in the above tissues. 
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4.3.15 Histology 
Refer to 2.4.11 for detailed procedure applied here. 
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4.4 Figures 
 
Figure 4.12 Scheme showing synthetic route from PRINT particles to surface-neutral microgels 
with charged interiors and functionalization of the microgels (A to E). Control particles with 
charged surface were produced following route A to H. 
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Figure 4.13  (A) Synthetic scheme for ADA by reacting HEA with 2-methoxylpropene in the 
presence of an organic acid PPTS. (B) NMR spectrum of ADA in CDCl3 measured at 25 
oC. 
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Figure 4.14  ADA crosslinked CEA containing particles at different stages. (A) as prepared; (B) 
after pH=3 treatment for 3 h; (C) PEGylated by mPEG5k-amine using EDC/NHS; (D) pH=3 
treatment for 18 h after PEGylation. 
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Figure 4.15  Fluorescent microscopic image of (A) freshly prepared particle A  and  (B) swollen 
particle F after acetal degradation in pH=3 buffer for 2 h.  (C) Size increase of particle A 
overtime in different pHs. Aliquots of particle suspensions were taken out and re-suspended in 
PBS for sizing by averaging diameter of particles under microscope (n=50).  
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Figure 4.16  Effect of PEGylation on ADA crosslinked AEM-particles. Fluorescent image of 
acid-treated particle A after PEGylation with unpurified (A) and purified (B) mPEG5k-NHS. 
Confocal microscopic image of model particles (7×7×3 µm cylinders) after reaction with (C) 
fluorescein-PEG2k-NHS and (D) fluorescein-NHS. 
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Figure 4.17  Standard curve for fluorescein-PEG2k-NHS regarding fluorescence excited at 492 
nm and emitted at 518 nm (3 readings averaged for each concentration). Starting from 1 mg 
dyeless particle A, the same numbers (5 × 10  ) of particle C and F were prepared respectively. 
Both C and F were reacted with 10 mg fluorescein-PEG2k-NHS for 12 h followed by thorough, 
repeated washing/centrifugation circles. The obtained particle suspensions were re-suspended in 
PBS to obtain concentration of 1 × 10  particles/mL for both particles. Then starting from this 
concentration, defined dilutions were made to fit into the linear range of the standard curve. 
Particle F reacted with mPEG2k-NHS for 6 h (needed time to acquire near-neutral zeta-potential) 
was also measured for amine content using this method. 
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Figure 4.18  Size and ζ-potential change of particles synthesized following route of (A) particle 
A to particle E and (B) particle A to particle H.  
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Figure 4.19  (A) The solutions of 4 mg Hb reacted with 1 mg particles (0.5 mL) of G (left) or D 
(right) for 6h. The aggregation for G could be avoided when conjugation was carried out at 
dilute concentrations (0.5 mg/mL particles). For all the in vitro and in vivo studies, the 
conjugation was carried out at low concentration for both G and D particles. (B) The optical 
density (720 nm to avoid Hb absorbance) change for hemoglobin loaded particles E and H 
dispersed in PBS containing 10% fetal bovine serum (900 µL particle suspension was mixed 
with 100 µL fetal bovine serum quickly in the cuvette before reading started). The optical 
density at 720 nm for the suspensions was read every 1 min over 15-20 h at 23 °C. 
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Figure 4.20  (A) Macrophage interaction with different particles. About 400 particles/cell dosed 
to a total of 105  Raw264.7 cells for each particle type. (B) Cytotoxicity of different particles to 
Raw264.7 cell line. 
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Figure 4.21  (A) Intravital microscopy images of mice earlobe blood vasculature imaged at the 
rhodamine (Rh) channel by injecting dextran70k-rhodamine prior to dosing particles, and imaged 
at the near-IR (NIR) channel just 100 secs after dosing particles (C, F, H). (B) Decrease in 
fluorescence of area of interest within 2 h of imaging by IVM (averaged of n=3). For each 
particle type, 107 particles/g body weight were dosed. 
A 
B 
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Figure 4.22   Fluorescent images of lung with nucleus stained by DAPI for mice injected with 
different particles (shown in purple from NIR dye) denoted on the right corner of each picture. 
All scale bars=20 µm. 
C F 
D G 
E H 
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Figure 4.23  Biodistribution of the different particles into various tissues 2 h postdosing 
presented by percent fluorescence normalized for tissue weight, with n=3 for each case.  
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
RBC, which can be regarded as a natural microparticle since it is anucleate (nucleus-
free), can circulate for 120 days in blood. This exceptionally long circulation time for a particle 
of such a size, is guaranteed by the unique combination of such factors: shape, modulus and 
surface properties that are found in RBCs. To date, out of the many RBC substitutes in the form 
of Hb-loaded particles, there is not a single one that mimics the size of true RBCs, not only 
because of inadequate control over size and size distribution, but more importantly lack of 
concurrent tuning of modulus. The long-standing dogma that microparticles would be quickly 
removed from circulation because of filtration by the lung was only challenged recently from our 
study that sufficiently deformable particles with the size of RBC could navigate the lung to 
circulate for extended times.1 
PRINT, a precision micro-molding technique that can generate uniform particles with 
tight control over size, shape, modulus and surface properties, allowed for hydrogel particles that 
mimick the size, shape, modulus of RBCs. Mimicking the size of RBCs for the fabrication of 
oxygen carrier is not trivial. A major hurdle that is difficult to overcome for most oxygen carriers 
is vasoconstriction due to scavenging of NO by Hb in these carriers.2 It is known that 
vasoconstriction is inversely proportional to the size of the carrier,3 making our RBC-sized 
oxygen carriers promising. It also seems to follow design rules that, for similarly deformable soft 
particles with a low modulus (6.5 kPa), RBC-sized particles could circulate longer than other 
particles with either larger or smaller sizes. Again, only through PRINT was such a study 
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possible as modulus could be firmly controlled by using identical formulation while size could 
be varied by using different molds. With the intention to extend circulation and avoid 
vasoconstriction, RBC-sized PRINT hydrogels seemed to be the best starting particles for 
fabricating Hb loaded oxygen carriers. 
The highly swollen nature of PRINT hydrogels allowed for diffusion of Hb even into the 
interior of particles, thus a high loading could be obtained. We could achieve a suspension of 
particles with [Hb] = 5.2 g/dL so far. The conjugation was carried out under mild conditions so 
that the structure and function of Hb could be well maintained. Since the reacting handles were 
originally distant from each other because of high swelling of particles, extra crosslinking could 
be avoided after conjugation, resulting in sufficient deformability of the protein-laden particles. 
This conjugation method can be applied to other proteins, such as BSA. Nevertheless, the 
uniform distribution of Hb in the particles also caused a drawback regarding the surface 
properties of particles, as it is well-known that surface-bound proteins could accelerate 
aggregation and MPS clearance of particles. 
Confined distribution of Hb within particles without surface exposure was obtained by 
designing a new type of PRINT hydrogel that had asymmetric distribution of functional groups. 
It is well accepted that charged particles would be cleared from circulation faster than neutral 
ones. Through the constricted PEGylation method, particles with neutral surface could be 
obtained with functional groups reserved to the interior. When Hb was conjugated to the 
particles, the protein would be exclusively installed in the interior. We investigated the in vivo 
behavior of three groups of particles where each group had the same interior characteristic but 
different surface properties, and found that particles with neutral surface had extended 
circulation than their charged counterparts. Most noteworthy is that surface-neutral particles 
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loaded with Hb managed to navigate the lung, while the control particles with Hb on the surface 
were rigorously filtered by the lung. Our results not only agreed with previous research regarding 
effect of particle surface on in vivo circulation, but also demonstrated that a non-dense layer of 
PEG on soft particles could achieve similar result as a dense layer of PEG did on solid particles. 
In summary, when one mimics the size, shape, modulus of RBCs as well as the 
distribution pattern of Hb within the particles, a viable RBC substitute seems evident. By 
PRINT, we have prominent control over the carrier particles. With preservation of Hb structure 
and function, we expect to see the Hb loaded particles act as an efficient oxygen carrier with 
minimal vasoconstriction and efficient oxygen delivery capacity. 
5.2 Future Directions 
5.2.1 Effect of ζ-potential on PK and BioD of Soft Particles 
The distribution map of RBC mimics can be completed by maintaining the size, shape, 
modulus of particles while varying the ζ-potential. Our study in Chapter 4 on particles with a 
neutral surface versus charged surfaces definitely indicates the importance of surface charge of 
particles on PK and biodistribuiton. It was also found that RBC mimics with ζ-potential of -32 
mV were cleared faster than that with -18 mV of ζ-potential. 
For true RBCs, there is a strict window of negative ζ-potential, out of which RBCs would 
be recognized by the MPS. To map out a window for ζ-potential that allows extended circulation 
of soft particles, future directions should consider the fabrication of the same-sized PRINT 
hydrogels with varied CEA amount in the formulation. However, as can be seen in Figure 5.1, 
particles with more CEA tend to swell more when made out of the same 2 µm mold. The 
modulus of particles with higher content of CEA may also be different (higher swelling does not 
necessarily mean lower modulus as it is possible that polymer chains can be so extended that 
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more stress is require for further deformation). Therefore, to control size, shape and modulus 
while varying ζ-potential may not be as easy as it seems to be. 
An indirect way to fabricate such particles with the same size, shape, modulus but 
different ζ-potential may be possible. Starting from PRINT hydrogels containing a fixed content 
of AEM (say 40%), different amounts of mPEG-NHS can be added to the swollen particles to 
quench the amine groups to varying extents, generating particles with different positive surface 
charges. Since PEG attached to an amine can still act as “repelling group” similarly to the 
originally charged amine, size and probably modulus of the resultant particles may still be 
similar when mPEG-NHS with a suitable MW is chosen. Our estimation is low MW (around 500 
Da) PEG may fulfill this purpose. Then the remaining amines in different particles can be 
converted to carboxyls by succinylation, generating soft particles with varying ζ-potential but a 
similar size and modulus. 
IVM studies of the particles with the same size, shape and modulus but varied ζ-potential 
can possibly map out a suitable window for ζ-potential that allows extended circulation for soft 
particles.  
5.2.2 Nerve Agent Scavenger 
Conjugation of Hb to PRINT RBC-sized hydrogels is a facile method that can be applied 
to other therapeutically-relevant proteins. Because of the large size, the RBC mimics cannot be 
used for delivery of proteins into cells. The application should be limited to proteins that can take 
effect during circulation. For such proteins with limited circulation half-life, conjugation into the 
RBC mimics can greatly improve the therapeutic availability.  
Of special interest is to load butylrylcholinesterase (BuChE) into the particles. Such 
particles can be used as bioscavenger to remove nerve agent in circulation over extended time 
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because BuChE is an efficient enzyme that can degrade phosphorous nerve agents. Using the 
CEA containing particles with a neutral surface, the circulation half-life of the scavenger may 
still be long enough even after BuChE loading since the loading ratio does not have to be as high 
as that of Hb in oxygen carriers. A compelling advantage of using PRINT hydrogel as the 
bioscavenger may arise from rapid diffusion of nerve agent into the swollen particles.  
5.2.3 Nucleic Acid Scavenging 
Free nucleic acid released from dying or dead cells may enter bloodstream and can be 
taken up by inflammatory cells and activate multiple nucleic acid-sensing toll-like receptors 
(TLRs). Over activation of these TLRs can cause a variety of inflammatory and autoimmune 
disease. Materials that can neutralize the proinflammatory effects of any nucleic acids regardless 
of it sequence, structure, or chemistry are highly sought after. Sullenger’s group developed a 
simple method to use cationic polymers as molecular scavenger to soak up and neutralize the 
inflammatory nucleic acids.4 However, one obvious drawback of the cationic polymers is their 
limited half-life in circulation. 
We had previously tested homogeneous cationic particles regarding nucleic acid binding 
capacity, and found that the particles could effectively bind DNA (Figure 5.). However, the 
particles were also highly cytotoxic. The surface-neutral, interior cationic RBC mimics 
synthesized may fit this application very well as nucleic acid scavenger. After binding with 
nucleic acids in bloodstream, the particles may become stiff and removed in the spleen. A proof-
of-concept experiment can be carried out by using the microfluidic device to test, after binding 
with varying amounts of DNA, if particles can still pass through or not. 
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5.2.4 Other Formulations for Soft Particles 
So far, we have utilized synthetic polymers as the matrix for soft particles, especially 
photocurable acrylates. Even though very low amount of long-chain crosslinker was used to 
decrease the crosslinking density, chain transfer reaction cannot be completely avoided 
especially with the presence of hydroxyl groups in HEA or HP3A. To further decrease the 
modulus of hydrogels so that even higher loading of proteins like Hb can still retain sufficient 
deformability, new materials may have to be explored. PEG hydrogel can be a good candidate 
because of absence of side groups in PEG and the flexibility of the main chain. While 
crosslinking density may still be high when PEG-diacrylate is used to construct PEG hydrogel, 
adding PEG-dithiol to decrease the crosslinking density and elongate the main chain may 
generate even softer hydrogel. The thiol-ene chemistry has been widely used to construct PEG 
networks from PEG-dithiol and PEG-diene or PEG-diacrylate.5 While those constructed PEG 
hydrogels had been mostly prepared in bulk for tissue engineering purposes with elastic modulus 
that could be around 1 kPa,6 there has been no report of making such soft hydrogels in the 
micron size. It is possible for us to PRINT such particles in a manner similar to PRINT PLGA 
particles. PEG-dithiol and PEG-diacrylate with high MW are solids with melting point around 65 
ºC. We can thermally fill the mold with the PEGs followed by photocuring. To ensure sufficient 
mobility of PEG molecules in the mold, we may need to heat the mold during UV curing. 
A completely new material, resilient-like-polypeptide (RLP) can also be used to fabricate 
protein-based soft hydrogel particles. Recombinant RLPs possess the favorable attributes of 
native resilin, which is the rubber-like protein found in specialized compartment of most 
arthropods with excellent mechanical properties including high resilience and low stiffness.7 
Using RLP as matrix, PRINT particles with low modulus and high resilience may be obtained, 
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and used for in vivo applications because of the biocompatibility. The deformability of RLP-
based microparticles may allow them to navigate small capillaries similarly to hydrogel particles, 
circulating for extended time. 
5.2.5 Nanoparticle Loading 
Generally speaking, nanoparticles are used to deliver therapeutics into tissues or cells, so 
there is no need to encapsulate nanoparticles in bigger carriers. However, there may be emerging 
areas that long circulating microgels like the RBC mimics discussed here can be used as mother-
ship carriers for nanoparticles. 
For nanoparticles that are supposed to stay and take effect in bloodstream without 
sequestration into specific tissues, the RBC mimics could help to extend their circulation time by 
trapping them inside. Here is an example. RBC membrane-coated PLGA nanoparticles prepared 
by Zhang’s lab had been an intriguing construct for toxin scavenger in vivo.8 Most toxins are 
pore-forming on the membrane of RBCs and endothelial cells. By coating mouse’s RBC 
membrane onto PLGA nanoparticles, the formed structure could efficiently bind toxins as decoy. 
Due to the nano-size of the PLGA particles, the total surface area of administered nanoparticles 
can be large enough to compete with RBCs so that toxins can be preferentially trapped by the 
nanoparticles. These RBC membrane-camouflaged PLGA nanoparticles could circulate a long 
time as they tested before.9 However, to make this technique really scalable, it is important to 
just use synthetic lipid membrane as coating to scavenge toxins. However, PLGA nanoparticles 
coated with synthetic lipid membrane cannot stay long enough in bloodstream. It will benefit 
greatly to load these nanoparticles in our RBC mimics to extend their circulation. 
A possible method to load nanoparticles into the RBC mimics is to incubate the 
nanoparticles with RBC mimics in DI water, in which the RBCs can swell more due to lowered 
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ionic strength. Then adding suitable amount of 10X PBS to the solution to obtain 1X PBS can 
instantly shrink the RBC mimics, also tightening the pores of the hydrogels to entrap 
nanoparticles.  
5.2.6 Hollow RBC Mimic 
The RBC mimics discussed in this dissertation, though mimicked the size, shape and 
deformability of RBCs, are structurally quite different from true cells. The particles were 
structurally homogenous hydrogels, while RBCs are fluid-filled sacs contained by a complex 
membrane that has extreme flexibility. The two different structures may possibly behave 
differently in flow, despite sharing similar mechanical properties. To mimic the structure of true 
cells, a hollow particle with membrane structure is desired. 
There have been enormous studies using layer-by-layer (LBL) technique to deposit 
polymers on sacrificial template particles in order to reproduce cell-like hollow capsules.10,11 
Generally, polymer films are coated onto colloid particles by depositing alternating layers of 
oppositely charged polymers sequentially. Other complementary layers containing hydrogen-
bonding polymers are also candidates for driving the assembly of polymer films onto particle 
surface. Crosslinking of the deposited polymer films is often needed to form a stable core-shell 
structure. Removal of the sacrificial core can generate hollow polymer capsules. Using LBL 
technique to coat polymers on spherical PLGA particles that had similar diameter as RBCs, 
Mitragotri’s group managed to generate a hollow membrane structure that mimicked RBCs by 
dissolving the PLGA core.12  
PRINT provides exciting opportunity to generate uniform particles that can be used as 
sacrificial template for synthesizing hollow membrane structures. PLGA PRINT particles can be 
used for this purpose. Other materials include polymers crosslinked by acid-labile monomers 
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such as ADA or silyl ether crosslinkers. While most hollow structures prepared by LBL method 
rely on spherical templates, we can explore the outcome when non-spherical particles are used. 
For example, disk-like particles can be used as template for constructing polymer membranes. 
Dissolving the sacrificial core may lead to highly collapsed polymer capsules that may deform 
more easily than capsules replicated from spherical particles.  
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5.3 Figures 
  
Figure 5.1  Fluorescent micrographs of HP3A particles with (A) 20 wt% and (B) 50wt% CEA. 
The size of the particles were 6.5 and 7.5 µm, and the zeta-potential were -23.5 and -29.9 mV 
respectively.  
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Figure 5.2    Cationic hydrogel particles. (A) Particles fluoresce in the green channel due to 
matrix bound fluorescein dye.  (B) Fluorescence in the red channel from adsorbed Cy3 dye-
conjugated DNA 20mer.  Particles were incubated at 37 ºC for one hour with 1 µM DNA, then 
washed 3 times to remove unassociated DNA.  Scale bars are 20 µm. 
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